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3To Axel and Iida
“Is not an event in fact more significant and 
noteworthy the greater the number of fortuities 
necessary to bring it about?” 
(Milan Kundera)
4ABSTRACT
European bat lyssavirus type 2 (EBLV-2) was first isolated in Finland from 
a Daubenton’s bat (Myotis daubentonii) in 2009. Rabies in bats was already 
suspected in 1985, when a Swiss biologist died in Finland of lyssavirus infection, 
later identified as EBLV-2 infection. However, the origin of the infection could not 
be confirmed at that time. In 1986, 183 bats were analyzed for lyssaviruses in active 
surveillance, and passive rabies surveillance was ongoing, but lyssavirus was not 
detected in bats before 2009. In 2010–2011, during another active surveillance 
study, samples from 774 bats were analyzed for EBLV viral RNA. In addition, 
sera from 423 bats were analyzed for the presence of lyssavirus antibodies. 
Antibodies were detected in 2010 and 2011 from two locations and from one 
location, respectively. All seropositive bats were Daubenton’s bats. All locations 
where seropositive bats were detected were in close proximity to where the EBLV-
2-positive Daubenton’s bat was found in 2009. No EBLV viral RNA was detected 
in any of these bats. In 2016, EBLV-2 was detected from a diseased Daubenton’s 
bat for the second time from a location about 100 kilometers from where the 
Daubenton’s bat was found in 2009. These data provide proof that EBLV-2 is 
endemic in the Finnish Daubenton’s bat population.
In phylogenetic analysis, the Finnish EBLV-2 strains formed a monophyletic 
group separate from other bat-type lyssaviruses with significant support. EBLV-2 
shared the most recent common ancestry with Bokeloh bat lyssavirus (BBLV) and 
Khujand virus (KHUV). EBLV-2 showed limited diversity compared to rabies virus 
(RABV) and appears to be well adapted to its host bat species. The slow tempo 
of viral evolution was evident in the estimations of divergence times for EBLV-2: 
the current diversity was estimated to have built up during the last 2000 years. 
In a phylogenetic tree of partial N gene sequences, the Finnish EBLV-2 strains 
clustered with strains from Central Europe, supporting the hypothesis that EBLV-2 
circulating in Finland might have a Central European origin. The Finnish EBLV-
2 strains and a Swiss strain (1993) were estimated to have diverged from other 
EBLV-2 strains during the last 1000 years, and the Finnish strains (1985 and 
2009) appear to have evolved from a common ancestor during the last 200 years.
Rabies vaccine is used to protect against rabies virus before or after potential 
exposure. Since all the currently available vaccines are based on RABV, the vaccines 
are also used to protect against other lyssaviruses, and additionally against EBLV-2 
infection based on cross-protection. We assessed the level of protection afforded 
by two commercial rabies vaccines, one for humans and one for animals, against 
intracerebral challenge in mice with EBLV-2 isolated from a bat in 2009. We 
compared this with protection using the same mouse model against challenge 
5with RABV isolated from a Finnish raccoon dog in 1989. When challenged with 
RABV, all the vaccinated mice survived. When challenged with EBLV-2, 75% to 
80% of the vaccinated mice survived. All vaccinated mice developed sufficient to 
high virus-neutralizing antibody (VNA) titers against RABV, ranging from 0.5 to 
128 IU/ml. RABV-based vaccines also appear to offer good cross-protection against 
EBLV-2 circulating in the Finnish bat population. 
To investigate the factors influencing the response to rabies vaccination, we 
assessed the success of vaccination measured from the antibody response in dogs 
(n = 10 071) and cats (n = 722) sampled during 2009–2013. We examined the 
factors influencing the response to vaccination when animals failed to reach a 
rabies antibody titer of ≥0.5 IU/ml. Of the dog and cat samples, 10.7% (95% 
confidence interval CI 10.1–11.3) and 3.5% (95% CI 2.3–5.0), respectively, had a 
vaccination antibody titer <0.5 IU/ml. In dogs, vaccination with two commercial 
vaccines (odds ratio OR ranging from 2.5 to 13.6), vaccination over six months 
previously (OR from 4.2 to 4.5), and vaccination of dogs >60 cm or larger (OR 
from 2.3 to 3.2) resulted in a higher risk of failing to reach an antibody level of 
at least 0.5 IU/ml. In dogs up to a year old, these risks were higher than in older 
dogs. In cats, the type of vaccine did not appear to play a role.  
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INTRODUCTION
Viruses from the genus Lyssavirus can cause a disease called rabies. Rabies is an 
acute encephalomyelitis that can affect all warm-blooded vertebrates, predominantly 
mammals. It has the highest case fatality rate of conventional infectious diseases, 
approaching 100%. Rabies caused by rabies virus (RABV) is responsible for about 
55 000 to 75 000 human deaths and 1.74 million disability-adjusted life years every 
year, mostly in Africa and Asia (Knobel et al. 2012). RABV is transmitted between 
mammals via bites, the domestic dog (Canis famialiaris) being the main source 
of rabies infections in humans. The true reservoir of lyssaviruses is thought to be 
bats (Chiroptera) (Kuzmin and Tordo 2012). In a small number of cases, rabies 
in humans and other mammals is caused by a lyssavirus other than RABV and is 
contracted from bats. Disease caused by other lyssaviruses resembles rabies caused 
by RABV and can therefore also be called rabies. Data on virus–host interaction 
is mostly based on knowledge of RABV, but appears to apply in many aspects to 
other lyssaviruses as well.
The Lyssavirus genus includes 14 recognized species: classical rabies virus 
(RABV), Lagos bat virus (LBV), Mokola virus (MOKV), Duvenhage virus (DUVV), 
European bat lyssavirus type 1 (EBLV-1), European bat lyssavirus type 2 (EBLV-
2), Australian bat lyssavirus (ABLV), Irkut virus (IRKV), West Caucasian bat virus 
(WCBV), Khujand virus (KHUV), Aravan virus (ARAV), Shimoni bat virus (SHIBV), 
Bokeloh bat lyssavirus (BBLV), and Ikoma lyssavirus (IKOV) (Anonymous 2017a). 
Novel lyssaviruses include Lleida bat lyssavirus (LLEBV), which was found in a 
bent-winged bat (Miniopterus schreibersii) in Spain in 2011 (Arechiga-Ceballos et 
al. 2013), and Gannoruwa bat lyssavirus (GBLV), which was isolated from a Greater 
Indian Fruit Bat in Sri Lanka in 2015 (Gunawardena et al. 2016). Lyssaviruses 
can be divided into phylogroups (Badrane et al. 2001). Phylogroup I comprises 
the classical rabies virus (RABV) and the majority of bat lyssaviruses (DUVV, 
EBLV-1, EBLV-2, ABLV, IRKV, KHUV, ARAV, BBLV, GBLV), whereas MOKV, 
LBV and SHIBV form phylogroup II (Badrane et al. 2001, Kuzmin et al. 2010, 
Gunawardena et al. 2016). WCBV, IKOV, and LLEBV may be representatives of 
possible new phylogroups (Kuzmin et al. 2005, Marston et al. 2012, Arechiga-
Ceballos et al. 2013).
In the Americas, bats are infected with rabies virus RABV, but outside the 
Americas, other lyssavirus species are present in bat populations. EBLV-2 is known 
to associate with two closely related Myotis bat species, Daubenton’s (Myotis 
daubentonii) and pond bats (M. dascyneme). EBLV-2 has caused two human 
deaths: in 1985 in Finland and in 2002 in the UK (Lumio et al. 1986, Roine et al. 
1988, Fooks et al. 2003).
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Rabies caused by RABV is preventable by pre- or post-exposure vaccination and 
the use of immunoglobulins in humans and by pre- and post-exposure vaccination 
of animals. However, all the currently available vaccines are based on RABV, and 
while they offer partial cross-protection against other lyssaviruses in phylogroup 
I, protection against lyssaviruses outside phylogroup I is considered poor.
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2 REVIEW OF THE LITERATURE
2.1 History of rabies research
Rabies is one of the oldest known diseases. Democritus, Aristotle, Hippocrates, 
and Celsus already described the clinical features of rabies and understood that it 
can be transmitted through the bite of a rabid animal. Cordamus assumed that a 
“poison” was present in a rabid dog’s saliva. Celsus wrote in the first century anno 
Domini (AD): “The patient is tortured at the same time by thirst and by invincible 
repulsion towards water”. A variety of literature in the period from 800–700 BC 
contained passages describing this disease. In Homer’s Iliad, Hector is compared 
to a rabid dog. Fracastotoro (1478–1553) proposed a theory of contagion. Morgagni 
(1735–1789) concluded that rabies was not transmitted by blood but via the nerves. 
Pathogenesis studies in the 1700s demonstrated that the infective agent of rabies 
was transmitted via saliva and could be transmitted between species. Louis Pasteur 
(1822–1895) started his work on rabies in 1880. By 1884, he and his colleagues 
had developed the first rabies vaccine, which was administered to a person in 
1885. Over the next decades, hundreds of thousands of people were treated with 
this vaccine at the Institut Pasteur in Paris. Neuroparalytic complications of early 
vaccines were noted, and in 1911, Sir David Semple reported on a method for 
preparing an inactivated vaccine, the Semple vaccine, which was widely used for 
several decades (Jackson 2013a, Kuzmin and Tordo 2012).
A diagnostic breakthrough was achieved in 1903, when Adolchi Negri observed 
eosinophilic cytoplasmic inclusion bodies in neurons in the brains of rabid dogs 
(Negri bodies). Remlicher discovered in 1903 that the etiological agent of rabies was 
ultrafilterable, and rabies virus was isolated for the first time. In the 1950s and the 
1960s, electron microscopic studies were performed on Negri bodies. Furthermore, 
in the 1950s, Goldwasser and Kissling used indirect fluorescent antibody staining 
(FAT) in order to demonstrate rabies virus antigen in impression smears of the 
brain of rabid animals. This technique played an important role in the first modern 
experimental pathogenesis studies, which demonstrated that rabies virus is highly 
neurotropic and that the virus spreads to the central nervous system in the axoplasm 
of peripheral nerves. In 1983, the first full-length rabies virus glycoprotein gene 
was cloned (Jackson 2013a, Kuzmin and Tordo 2012). 
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2.2 Lyssaviruses within the family Rhabdoviridae
Rabies is caused by RNA viruses belonging to the genus Lyssavirus within the 
family Rhabdoviridae in the order Mononegavirales. The name of the genus 
originates from Greek mythology. Lyssa was a goddess or spirit of rage, fury, raging 
madness, and frenzy. The type virus of this genus is rabies virus RABV (Dietzgen 
and Kuzmin 2012).
Genetically, lyssaviruses form a very tight monophyletic cluster within the 
Rhabdoviridae. Species demarcation is based on antigenic cross-reactivity using 
polyclonal antisera and monoclonal antibodies, on genetic characteristics, topology 
and consistency of phylogenetic trees and ecological characteristics. The Lyssavirus 
genus includes fourteen species that have been accepted by the International 
Committee on Taxonomy of Viruses: classical rabies virus (RABV), Lagos bat virus 
(LBV), Mokola virus (MOKV), Duvenhage virus (DUVV), European bat lyssavirus 
type 1 (EBLV-1), European bat lyssavirus type 2 (EBLV-2), Australian bat lyssavirus 
(ABLV), Irkut virus (IRKV), West Caucasian bat virus (WCBV), Khujand virus 
(KHUV), Aravan virus (ARAV), Shimoni bat virus (SHIBV), Bokeloh bat lyssavirus 
(BBLV) and Ikoma lyssavirus (IKOV) (Anonymous 2017a). There are two novel 
tentative lyssaviruses, Lleida bat lyssavirus (LLEBV) (Arechiga-Ceballos et al. 2013) 
and Gannoruwa bat lyssavirus (GBLV) (Gunawardena et al. 2016). The timeline 
of different lyssavirus discoveries is presented in Figure 1, and the phylogenetic 
relationship of different lyssaviruses in Figure 2.
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Figure 2. A phylogenetic analysis of the lyssaviruses. The analysis is based on 405 nucleotides 
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Phylogenetic an lyses and the virus–host relationshi  suggest that all 16 
currently known species of lyssaviruses probably originated in bats. With the 
exc ption of Mokola virus and Ikoma lyssavirus, all other lyssaviru  species have 
be n isolated from bats. Most lyssaviruses have a limited geograp ical distributi  
and are also limited to a certain host species. RABV has a worldwide distribution 
and has adapted to several different hosts (Table 1).
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Table 1. Viruses currently included in the genus Lyssavirus
Recognized 
and proposed 
lyssavirus 
species
Natural host Year and 
place of first 
isolation
Geographical 
range
Known 
human 
cases (n)
Phylo-
group
Remarks
Rabies virus 
(RABV)
Terrestrial mammals 
                         
Bats of multiple 
species
1903 Turkey Worldwide 
New World
Yes 
(55000/y)
Yes 
(100/y)
I Causes the vast majority 
of human cases in the 
world. 
European bat 
lyssavirus type 
1 (EBLV-1)
Insectivorous bats 
(predominantly 
Eptesicus serotinus)
1954 
Germany
Europe Yes (1) I Spillover infections to 
wild and companion 
animals have been 
documented.
Lagos bat virus 
(LBV)
Several fruit and 
insectivorous bat 
species
1956 Nigeria Sub-Saharan 
Africa
No II Spill-over infections to 
wild and companion 
animals have been 
documented. Constitutes 
several lineages. 
Mokola virus 
(MOKV)
Unknown 1968 Nigeria Sub-Saharan 
Africa
Yes (1) II Isolations from wild and 
domestic mammals.
Duvenhage 
virus (DUVV)
Insectivorous bats 1970 South 
Africa
Sub-Saharan 
Africa
Yes (3) I
European bat 
lyssavirus type 
2 (EBLV-2)
Insectivorous bats 
(Myotis daubentonii, 
M. dasycneme)
1985 Finland Europe Yes (2) I
Aravan virus 
(ARAV)
Insectivorous bat 
Myotis blythii
1991 
Kyrgystan
Central Asia No I Known by a single 
isolate.
Australian 
bat lyssavirus 
(ABLV)
Pteropodid bats of 
several genera and 
insectivorous bats
1996 
Australia
Australia Yes (3) I Spillover infections 
to horses have been 
documented.
Khujand virus 
(KHUV)
Insectivorous bat 
Myotis mystacinus
2001 
Tajikistan
Central Asia No I Known by a single 
isolate.
Irkut virus 
(IRKV)
Insectivorous bat 
Murina leucogaster
2002 
Russian 
federation
Eastern Asia Yes (1) I Known by three isolates.
West 
Caucasuian bat 
virus (WCBV)
Insectivorous 
bat from genus 
Miniopterus
2002 
Russian 
Federation
South-eastern 
Europe
No III/IV? Known by a single 
isolate.
Shimoni bat 
virus (SHIBV)
Insectivorous 
bat Hipposideros 
commersoni
2009 Kenya Kenya No II Known by a single 
isolate.
Ikoma 
lyssavirus
Unknown 2009 
Tanzania
Tanzania No III/IV? Known by a single 
isolate from Civettictis 
civetta. 
Bokeloh bat 
lyssavirus 
(BBLV)
Insectivorous bat 
Myotis nattereri
2010 
Germany
Germany, 
France
No I
Lleida bat 
lyssavirus 
(LLEBV)
Insectivorous 
bat Miniopterus 
schreibersii
2012 Spain Spain No III/IV? Known by a single 
isolate.
Gannoruwa 
bet lyssavirus 
(GBLV)
Pteropus spp 2014 Sri 
Lanka
Sri Lanka No I Known by four isolates.
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2.3 Structure of the virion, genome, and proteins
Lyssaviruses have large enveloped virions, 100–430 nm in length and 45–100 nm 
in diameter, with a bullet-shape or cone-shaped morphology. They are composed of 
an infectious nucleocapsid enveloped by a host-derived lipid membrane containing 
glycoprotein spikes.
Figure 3. Structure of a lyssavirus.
http://viralzone.expasy.org/all_by_species/22.html
Reprinted with permission from ViralZone, Swiss Institute for Bioinformatics
The negative-sense, single-stranded lyssavirus genome is about 12 kb in length and 
it encodes five proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), 
glycoprotein (G), and RNA polymerase (L), in the order 3′-N-P-M-G-L-5′. Each 
gene is flanked by intergenic regions with a high degree of divergence (Marston 
et al. 2007). The variation within genomes could be related to polymerase errors 
during replication (Assemberg et al. 2010).
Figure 4. Genetic organization of lyssaviruses.
http://viralzone.expasy.org/all_by_species/22.html
Reprinted with permission from ViralZone, Swiss Institute for Bioinformatics
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2.4 Virus–host interactions
2.4.1 Pathogenesis
Lyssaviruses are highly neurotropic. The lyssavirus replicates in limited numbers 
in the peripheral tissue at the site of inoculation. It spreads along peripheral nerves 
and the spinal cord to the central nervous system, where it disseminates and 
replicates, causing acute encephalomyelitis. From the central nervous system, it 
spreads along nerves to various organs, including the salivary glands. It has been 
shown that the lyssavirus remains at or near the entry site for most of the long 
incubation time. The incubation time in humans is usually between 20 to 90 days. 
There is uncertainty over what happens during the incubation period. The infection 
of muscle fibers may be a critical pathogenetic step for the virus to gain access to 
the peripheral nervous system, but studies also suggest that rabies virus is capable 
of direct entry into peripheral nerves (Jackson and Fu 2013)
The virus glycoproteins enable the virus to bind to neurospecific receptors 
and to gain entry into cells. At least three receptors have been proposed: nicotinic 
acetylcholine receptor, neural cell adhesion molecule receptor, and low-affinity 
p75 neurotrophin receptor. The virus spreads from the peripheral entry site to 
the central nervous system by retrograde fast axonal transport within motor and 
perhaps also sensory axons. This occurs at a rate of 50 to 100 mm per day. Infection 
also occurs early in motor neurons in the spinal cord and primary sensory neurons 
in dorsal root ganglia. Once central nervous neurons are infected, there is rapid 
dissemination of the virus along neuroanatomical pathways. Centrifugal spread 
to peripheral sites is essential for transmission of the virus to its natural hosts, 
and salivary gland infection enables the transmission of infectious oral fluids. 
The lyssavirus can also be detected in the retina and cornea, hair follicles, tongue, 
adrenal glands, heart, liver, and pancreas (Jackson and Fu 2013).
2.4.2 Clinical signs
Bats are the natural reservoir of lyssaviruses. The detection of seropositive bats 
without clinical signs suggests that bats can be infected and clear the infection. 
Lyssavirus infection can also cause clinical disease in bats. Furthermore, a long 
incubation period associated with infection has been recorded (Banyard et al. 
2014). When clinical disease is present, bats are often weak and unable to fly. 
They show abnormal behavior, uncoordinated movements, spasms, and paralysis. 
Infected bats are grounded, agitated, and aggressive, and they may make repeated 
attempts to bite. There are no observations that bats can survive infection if the 
clinical disease develops (Banyard et al. 2011).
The initial clinical signs of rabies in animals are often non-specific and may 
include lethargy, poor appetite, and diarrhea or vomiting. The clinical condition 
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progressively deteriorates. Changes in behavior are one of the first signs. An animal 
may become more reclusive or attention-seeking, and it might unpredictably and 
intermittently attack humans, other animals, or any object it comes into contact 
with. A wild animal might move slowly or act tame. There may be irritation or 
parasthesis at the site of initial entry of the virus. Saliva production increases and 
the ability to swallow decreases. Pupil size may be unequal, and there might be 
facial and tongue paresis and phonation changes. In the end stage, animals become 
paralytic, comatose, and moribund. The infection leads to death within ten days 
after the appearance of clinical signs (Hanlon 2012). 
Non-specific prodromal symptoms in humans include fever, chills, malaise, 
fatigue, insomnia, anorexia, headache, anxiety, and irritability for up to 10 days 
prior to the occurrence of neurological symptoms. About 80% of patients develop 
an encephalitic form of rabies, also known as a furious form, and the rest develop a 
paralytic form. In the encephalitic form, people suffer from generalized arousal or 
hyperexcitability separated from lucid periods. Intermittent episodes of confusion, 
hallucination, agitation, and aggressive behavior may occur. There might be 
symptoms of autonomic dysfunction. From 50% to 80% develop hydrophobia, 
a characteristic symptom of rabies. Encephalitic rabies leads to flaccid paralysis, 
coma, and multiple organ failure. Death occurs within 14 days of the onset of clinical 
symptoms. In paralytic or dump rabies, flaccid muscle weakness develops early in 
the course of the disease (Jackson 2012b). There are some differences in the clinical 
manifestations of dog- and bat-acquired RABV rabies cases. Encephalopathy, 
hydrophobia, and aerophobia have been reported to be more common in dog-
acquired rabies. Bat-acquired cases were more often misdiagnosed and lacked a 
bite history. Abnormal cranial nerve, motor, and sensory examinations, tremor, 
myoclonus, local sensory symptoms, symptoms at the exposure site, and local 
symptoms in the absence of a bite or scratch were more common in patients with 
bat-acquired rabies (Udow et al. 2013). 
The clinical disease of the Swiss biologist who died in Finland in 1985 of EBLV-
2 infection lasted for 23 days, and was a combination of the paralytic and furious 
forms of rabies. Severe ascending destruction of the brain was observed. An unusual 
progression from isolated brainstem death to cortical brain death occurred (Roine 
et al. 1988). The second case of human rabies due to EBLV-2 from the UK in 
2002 presented with rabies that had mixed components of furious and paralytic 
forms, which was strikingly similar to the EBLV-2 case from Finland (Nathwani 
et al. 2003).
2.4.3 Pathological changes
Despite the severe clinical neurological signs, the neuropathological findings are 
usually quite mild. Rabies results from neuronal dysfunction rather than structural 
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damage. The macroscopic examination is unremarkable or it shows a spectrum 
of mild and non-specific changes such as edema, congestion of blood vessels, 
and petechiae. Microscopic findings include mononuclear inflammatory cell 
infiltration, microglial activation and neuronophagia. The presence of Negri body 
viral inclusions in the cytoplasm is a unique and diagnostic feature of infection with 
rabies, but it is only present in about 40% of cases. There are marked abnormalities 
in dendrites and axons, vacuolation in neurons, and axonal swelling. These 
morphological changes may be sufficient to explain the clinical disease (Rossiter 
and Jackson 2013). In the EBLV-2 human case of 1985, the patient’s brain showed 
severe lytic changes (Roine et al. 1988).
2.4.4 Immunology
Infection induces the expression of innate immunity, inflammatory cells in 
the central nervous system, and apoptosis. The latter two correlate with the 
enhancement of permeability of the blood–brain barrier and the attenuation of 
the lyssavirus (Lafon 2013).
Lyssavirus causes an innate immune response, which involves the release 
of type I interferons, inflammatory cytokines and chemokines, the activation of 
complement, and the attraction of macrophages, neutrophils, and NK cells to 
eliminate the virus locally at the entry site and set up a specific immune response 
of B and T cells extraneurally. The innate immune response is triggered within 
hours after the entry of the virus and it is not pathogen specific. After its entry into 
nerves, lyssavirus elicits an innate immune response in the infected neurons, which 
are protected from destruction by infiltrating T cells and by mechanisms limiting 
the inflammation of neuronal tissue. Down-regulation of immune responsiveness 
in the periphery facilitates the propagation of the virus in the nervous system 
(Lafon 2013).
An adaptive immune response is tailored against a specific microbe and it 
takes several days to develop. The triggering of the adaptive immune response 
takes place in lymphoid organs such as the lymph nodes or spleen. The CD4 (T 
helper) and CD8 (cytotoxic T) lymphocytes recognize foreign antigens. The CD4 
cells limit the proliferation of pathogens, provide help for antibody production by 
B cells and CD 8 cells kill infected cells via cytotoxicity. A strong B cell response is 
mounted in the spleen. The entry of B cells into the infected neural system and the 
secretion of antibodies contribute to the clearance of the virus from the nervous 
system (Lafon 2013). The type of immune response where antibodies are found in 
body fluids is called a humoral immune response, while the type where specialized 
cytotoxic cells destroy virus infected cells is called a cell-mediated immune response 
(Tizard 2013). The primary correlate of protection is the presence of neutralizing 
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antibodies. Cell-mediated immunity is important and acts in synergy with the 
humoral response (Moore et al. 2006).
In rabies, clearance of the infection by T cells is inefficient and is inactivated 
by the virus: the cells undergoing death are the leucocytes and not infected 
neurons. During the course of encephalitic lyssavirus infection, B cells are almost 
undetectable in the brain (Lafon 2013). In the majority of human rabies cases, there 
is no detectable antibody response until some days after the development of clinical 
disease (Johnson et al. 2010). The limited immune response of the host could be due 
to a number of factors. The virus primarily replicates in the nervous system, which 
is an immunoprivileged location, and the induction of inflammation in the central 
nervous system is tightly regulated in order to avoid neuronal deficit of the host. 
It is also suggested that the infectious dose during a bite is too small to trigger an 
immune response, enabling the virus to infect nerves. The lack of antibodies could 
be a result of immunosuppression induced by the virus (Johnson et al. 2010). In 
mice, there is an increase in inflammatory cytokines and chemokines in response 
to EBLV-2 infection, which leads to a dramatic increase in T cell infiltration and 
provides evidence for a robust immune response to lyssavirus infection that may 
not commonly occur in RABV infection (Mansfield et al. 2008).
2.5 Vaccines 
2.5.1 Rabies vaccines
Rabies vaccines are defined as a standardized formulation containing defined 
amounts of immunogens, which are either inactivated (killed), live-attenuated, 
or biotechnology derived. Rabies vaccines are formulated for their specific purpose 
and for application by either the injectable or oral route, and they are produced in 
eggs or in cell culture. Vaccination is highly effective at preventing disease when 
administered before or shortly after exposure to rabies virus. Since Pasteur’s first 
rabies vaccine in 1885 until about the mid-twentieth century, rabies vaccines were 
based on virus grown in inoculated animals. Over the past 35 years, several safer 
and more potent vaccines have been developed by growth in cell cultures: human 
diploid cell vaccine, purified chick embryo cell vaccine, purified Vero cell vaccine, 
and purified duck embryo vaccine (Anonymous 2016).
All currently available vaccines are based on RABV. Studies have been conducted 
to investigate the cross-neutralization of sera against different lyssaviruses and 
cross-protection challenge. Consequently, they offer variable cross-protection 
against other lyssaviruses (Horton et al. 2010, Brookes et al. 2005a, Malerzyk 
et al. 2009, 2014, Hanlon et al. 2005, Liu et al. 2013). Protection is inversely 
related to the genetic distance of the lyssavirus in comparison to RABV (Brookes 
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et al. 2005, Malerczyk et al. 2009, Fekadu et al. 1988). However, there are no 
official recommendations by WHO on whether there would be a need to modify 
the current procedure for the pre- and post-exposure treatment of people or other 
mammals who are exposed to other lyssaviruses than RABV (Anonymous 2013, 
Anonymous 2016).
Moreover, a question has been raised about whether there would be need or 
means to develop a pan-lyssavirus vaccine. More cross-reactive vaccine formulations 
may be necessary in areas where a threat to the human population comes from 
lyssaviruses other than RABV. Recent advances in the antigenic characterization 
of different lyssaviruses will aid in future cross-reactive vaccine design. Studies 
have concentrated on the development of recombinant viruses or glycoproteins 
as potential novel vaccines, or swapping domains within the G protein between 
different lyssaviruses to produce a cross-phylogroup antibody response. However, 
there is a potential for the development of novel pan-lyssavirus vaccines from 
inactivated preparations of viruses from each phylogroup (Evans et al. 2012).
2.5.2 Response to vaccination
Factors associated with the success of rabies vaccination and antibody detection 
depend on the vaccine, the receiver of the vaccine, the person vaccinating, sampling, 
and the methods used to evaluate the success of vaccination (Figure 5).
Figure 5. Factors associated with the success of rabies vaccination and antibody detection.
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Because laboratory methods to measure the humoral response are easier to 
perform than those measuring the cellular response, VNA tests are used to verify 
that an immune response has occurred (Moore et al. 2006). According to WHO 
recommendations, 0.5 IU/ml is a sufficient antibody level, considered to represent 
a level of immunity in humans that correlates with the ability to protect against 
rabies infection (Anonymous 2013). The same threshold titer is applied in dogs, cats, 
and ferrets to confirm a satisfactory response to vaccination before international 
transportation.
Rabies vaccines differ in how they induce the antibody level of 0.5 IU/ml in 
dogs (Berntsson et al. 2011, Mansfield et al. 2004, Minke et al. 2008, Kennedy et al. 
2007). This may be due to differences in the immunogenicity of the vaccines or the 
potency of the vaccine batches. The antibody level peaks at slightly different times 
after vaccination with different vaccines, and the level starts to decline afterwards 
(Mansfield et al. 2004). In post-vaccination serological studies, the percentage of 
dogs with inadequate titers has been 3.1–8.1% (Sihvonen et al. 1995, Mansfield et 
al. 2004, Berndtsson et al. 2011), and for cats 2.85% (Mansfield et al. 2004). As 
many as 53% (95% CI 41% to 65%) of imported rescue dogs from Eastern Europe 
were found to have inadequate titers after rabies vaccination (Klevar et al. 2015).
Some individuals respond to vaccination earlier and produce high titers, while 
others respond later and produce lower titers (Moore et al. 2006). There are reports 
that vaccinated animals without detectable antibodies survive challenge, indicating 
that other immune mechanisms protect against rabies infection. On the other hand, 
the presence of detectable neutralizing antibodies to rabies at the time of challenge 
does not indicate protection for all the animals (Aubert 1992, Hooper et al. 1998). 
An active immune response and antibody response induced by rabies vaccines is 
measurable 7–10 days after vaccination. Responses in humans generally persist 
for two to three years, and even up to twenty years after vaccination (Moore et al. 
2006). The time between vaccination and sampling is a significant factor when 
estimating the immune response of an animal. In addition, the laboratory tests used 
to measure the immune response vary and the results are not always comparable. 
On the population level for rabies, the critical, theoretical vaccination coverage 
required to control the disease needs to be about 20% to 40% of the dog population. 
In practice, the achievement of this goal is hampered by factors responsible for 
a decline in the proportion of the vaccinated population over time. Empirically, 
consecutive annual vaccinations that achieve 70% vaccination coverage have proven 
effective in eliminating dog rabies (Knobel et al 2013).
2.5.3 Vaccination failures
There are many reasons why vaccination might not lead to protective immunity. 
The vaccine might be ineffective if it contains the wrong strain of antigen or the 
24
amount of antigen is insufficient. There can be a fault in the manufacturing process, 
the cold chain during transport, or in the storage of the vaccine (Tizard 2013). 
Incorrect administration can also cause vaccination failure. 
Even animals given an adequate dose of an effective vaccine may fail to be 
protected. The vaccine might be given too late if the animal is vaccinated during 
the incubation period, or the animal may fail to mount an immune response. 
Heavily parasitized or malnourished animals might be immunosuppressed, and 
some virus infections induce immunosuppression. Stress, pregnancy, extremes 
of cold or heat, fatigue, and malnutrition reduce the normal immune response. 
The most common reason for failing to respond to vaccination is the presence of 
maternal antibodies (Tizard 2013). Maternal antibodies may interfere with immune 
responses, particularly in puppies eight weeks of age or younger vaccinated with 
modified live rabies vaccine under field conditions (Aghomo et al. 1990). However, 
at least under experimental conditions, maternal antibodies and the immune 
function may not limit the immune response to inactivated vaccines that stimulate 
both B cell and T cell responses (Siegrist 2012). World Health Organization (WHO) 
guidelines recommend that all dogs, including puppies less than three months of 
age, are vaccinated during mass vaccination campaigns (Anonymous 2013).
2.6 Epidemiology
2.6.1 Epidemiology of bat-related lyssaviruses other than RABV
Those lyssaviruses for which an adequate number of isolates exist are bat-specific 
virus variants that are maintained in particular bat species within a geographically 
limited area. In Europe, EBLV-1, EBLV-2, BBLV, and LLBLV have been detected 
in bats. During 1977–2016, 1179 rabies cases (7.1% of all bats tested) were reported 
in 11 of the 45 known indigenous bat species in 20 European countries, most cases 
being EBLV-1. The majority of cases were detected in the Netherlands, Germany, 
Denmark, Poland, France, and Spain (WHO Rabies Bulletin Europe).
The first isolation of EBLV-2 from a bat took place in 1987 from a pond bat in the 
Netherlands (Nieuwenhuijs 1987). Elsewhere in Europe, EBLV-2 has sporadically 
been isolated from the Daubenton’s bat in Switzerland (Megali et al. 2010), the 
UK (Whitby et al. 2000, Harris et al. 2007), Germany (Freuling et al. 2008), and 
Finland (Jakava-Viljanen et al. 2010). In 2013, EBLV-2 was found from two Danish 
Daubenton’s bats using a molecular diagnostic strategy (Rasmussen et al. 2014) 
and in Norway in a Daubenton’s bat (Moldal et al. 2017).
In the UK, the first EBLV-2 positive bat was reported in 1996, and EBLV-2 
has been isolated from 15 Daubenton’s bats in the UK since 1996 (Johnson et 
al. 2016). In 2003, a seroprevalence of 0.05% to 3.8% in Daubenton’s bats was 
25
recorded. However, the virus was not detected from the 218 swabs tested (Brookes 
et al. 2005a). A study from 2003 to 2006 revealed a seroprevalence of 1.0% to 
4.1% (Harris et al. 2009). Live EBLV-2 was first isolated in Scotland in 2009. A 
single oral swab sample from a Daubenton’s bat was positive out of ca. 900 tested 
(reviewed in Schatz et al. 2013). These data suggest that EBLV-2 circulates at low 
levels in the UK and Scotland. 
In Switzerland, 837 bats were examined between 1976 and 2009 and three 
samples were found to be positive for EBLV-2. During active surveillance in 2009, 
one oral swab out of 237 was positive for EBLV-2 and three Daubenton’s bats were 
seropositive (Megali et al. 2010). EBLV-2 was first isolated in Germany in 2007. 
Between 1997 and 2007, a total of 1800 bats were tested in Germany, including 
45 Daubenton’s bats and one pond bat (Freuling et al. 2008). In the Netherlands, 
5 pond bats were found to be positive for EBLV-2 out of 129 pond bats analyzed, 
resulting in a prevalence of 3.9%. No new cases have been detected since 1997 
(Freuling et al. 2008, Van der Poel et al. 2005).
Virus-neutralizing antibodies have been found in many bat species throughout 
Europe. Due to cross-reactivity between different lyssaviruses, seropositivity cannot 
be linked to a specific lyssavirus (Schatz et al. 2013). Fourteen Daubenton’s bats 
sampled in 2008–2013 in Sweden had antibodies against lyssavirus when using 
EBLV-1 or EBLV-2 as an antigen (Hammarin et al. 2016). Seropositive Daubenton’s 
bats have also been found in the UK, Switzerland (Schatz et al. 2013), Finland 
(Nokireki et al. 2013), and Latvia (Dobrostana et al. 2017).
No spillover of EBLV-2 to other animals has been detected. In experimental 
infections, EBLV-2 has been shown to cause fatal disease in foxes (Cliquet et al. 
2009), sheep (Brookes et al. 2007), and mice (Banyard et al. 2014, Healy et al. 
2013). In Europe, spillover of EBLV-1 has been seen in natural infections of stone 
marten (Martes foina) (Müller et al. 2004), sheep (Tjørnehøj et al. 2006), and 
domestic cats (Tjørnehøj et al. 2004). Spillovers of Lagos bat and Mokola viruses 
have been recorded in cats, dogs, and wild carnivores and Australian bat lyssavirus 
in horses (Markotter et al 2006, Sabeta et al 2007. Shinwari et al 2014).
2.6.2 Epidemiology of rabies virus RABV
In the new world, bats are infected with RABV, and RABV has not been detected 
in bats outside the Americas. A rabies virus variant from hematophagous bats 
causes between 100 000 and 500 000 cattle deaths per year in Latin America, and 
spillover to cats, foxes, and other mammals has occurred (Barrett 2011).
Among domestic animals, dogs are the most important animal reservoirs for 
spillover cases of RABV to humans, whereas within wildlife species, foxes, raccoons, 
and skunks constitute the greatest threat to spillover to both humans and domestic 
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animals. The rabies situation in wildlife is complicated due to the presence of 
different terrestrial and bat vector species. 
In Europe, the red fox (Vulpes vulpes) has been the main reservoir of RABV. The 
raccoon dog (Nyctereutes procyonoides) was introduced into Europe in the 1920s, 
and could also act as a reservoir, since it played a significant role in the epidemiology 
of rabies in Eastern and Central Europe. In the USA, terrestrial species may be 
limited in their distribution, with raccoons (Procyon lotor) being present across 
much of the eastern United States, the gray fox (Urocyon cinereoargenteus) in 
Arizona and Texas, and both red and arctic (Alopex lagopus) foxes in Alaska and 
parts of Canada. In Asia and Africa, dog-mediated urban rabies is epidemiologically 
the most important form of rabies (Hanlon 2013)
Host switching has been proposed to be the evolutionary mechanism of 
lyssaviruses. Lyssaviruses have evolved through spillover from bats to terrestrial 
mammals. Such transmission to a novel host can alter the genome to enable efficient 
replication and maintenance within the recipient species. Host switching can lead 
to the evolution of a novel human pathogen. In most cases, spillover infections are 
dead-end infections. However, further transmission within new species may occur 
if productive infection and viral excretion take place (Badrane and Tordo 2001). 
Two case reports provide evidence for the maintenance of virus in a terrestrial 
species following presumed transmission from a bat species. In 1993, a small 
outbreak of rabies cases occurred in foxes on Prince Edward Island, Canada. The 
genetic detection of a bat RABV variant within this fox population was confirmed, 
and from the detection of low levels of virus in salivary gland material, it was 
assumed that some degree of intraspecific transmission among the foxes had 
occurred (Daoust et al. 1996). There was a second case in Arizona, USA, in 2001 
of an infection of a number of skunks with a bat RABV variant. This virus was 
phylogenetically most similar to that known to be present in populations of 
Eptesicus and Myotis spp. from the same region (Leslie et al. 2006).
2.6.3 Human rabies of bat origin
In the 16th century, it was reported that many soldiers died as a result of 
hematophagous bat bites in Darien, located south of what is now known as 
Panama. However, the link between hematophagous bat bites and rabies was not 
established until the beginning of the 20th century. Presently, it is well known that 
insectivorous, frugivorous, and hematophagous bats in the Americas act as wildlife 
reservoirs for the rabies virus and can transmit the disease to humans (Johnson et 
al. 2010). A rabies virus variant in hematophagous bats in Latin America causes a 
significant number of human deaths, estimated to be around 100 each year. In the 
USA, around 1 to 4 human deaths occur each year following bites by insectivorous 
bats (Barrett 2011).
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A small number of rabies cases in humans result from other lyssaviruses present 
in bats. Although numerous human contacts with European bat species have been 
reported, primarily from handling sick or injured animals (Brass 1994), only a 
few EBLV-induced human casualties have been conclusively demonstrated: in 
Voroshilovgrad, Ukraine (1977), in Belgorod, Russia (1985), in Finland (1985), and 
in the UK in Scotland (2002) (Botvinkin et al. 2003, Anonymous 1986, Lumio et al. 
1986, Roine et al. 1988, Fooks et al. 2003). The Russian case was genetically typed 
as being EBLV-1a, while the Ukrainian case was assumed to be EBLV-1 based on 
antigenic profiling (Botvinkin et al. 2003, Selimov et al. 1989). The virus variants 
responsible for human rabies cases in the UK and Finland were typed as being 
EBLV-2a and b, respectively (Fooks et al. 2003). Subsequently, two other human 
rabies cases following a bat bite have been described in the Ukraine (Botvinkin 
et al. 2003). However, these cases were clinically diagnosed and on the basis of 
anamnesis, and no virological or pathological results are available. 
A human case due to a bat contact was reported from Africa in 1970, which 
led to the isolation of Duvenhage virus. Two additional human cases, from 2006 
and 2007, have been reported. One confirmed lethal Mokola virus infection was 
documented from Nigeria in 1969 (reviewed in Johnson et al. 2010). In Queensland, 
Australia, ABLV has caused three human cases of rabies, two in the late 1990s and 
one in 2013 (Samaratunga et al. 1998, Hanna et al. 2000, Francis et al. 2014). In 
2007, a fatal human case of a bat lyssavirus infection occurred in Primorye Territory 
(the Russian Far East). The nucleotide sequence was closest to the bat lyssavirus 
species Irkut virus (IRKV), with 95% identity. IRKV had been isolated earlier from a 
dead greater tube-nosed bat (Murina leucogaster) in Irkutsk (Leonova et al. 2009).
2.7 Control and prevention
2.7.1 Human rabies
Rabies caused by RABV in humans is preventable by the promotion of behavior that 
prevents exposure to rabid animals, by eliminating rabies from dog populations, 
and by the administration of pre-exposure vaccination or emergency post-exposure 
treatment if such exposure should occur. Appropriate prophylaxis given within a 
short time after exposure prevents the occurrence of rabies. After possible exposure, 
the wound, abrasion, and splashes are first cleansed with water and soap for 15 
minutes and then disinfected. After cleaning, medical advice should be sought 
immediately (Anonymous 2013).
The control of rabies in humans needs to include rabies control in the reservoir 
species. Programs to increase awareness among the general public of the benefits 
of responsible dog ownership, basic care of suspected rabid bites, and avoiding 
28
animal exposure is promoted through campaigns and child education. People are 
educated to avoid contact with possibly infected animals, including bats, and use 
exclusion housing or netting to prevent bats from entering the house. Bites and 
scratches can be avoided by the use of appropriate protective clothes and a proper 
handling technique.
Rabies biologics for humans include vaccines and rabies immune globulins 
(RIG). The former are used for both pre- and post-exposure prophylaxis, and 
the latter only during post-exposure prophylaxis. The administration of RIG is 
intended to provide an immediate supply of rabies-neutralizing antibodies until 
the production of active immunity in response to vaccine administration. This 
immunity only persists for a short time, but the idea is to intervene before the virus 
reaches the nervous system (Rupprecht and Slate 2012). Pre-exposure prophylaxis 
does not eliminate the need for post-exposure prophylaxis after possible exposure, 
but it simplifies the post-exposure treatment so that two doses of vaccine separated 
by three days are sufficient.
Pre-exposure prophylaxis vaccination is recommended for anyone who is at 
continual, frequent, or increased risk of exposure to the rabies virus as a result of 
their residence or occupation, such as laboratory workers, veterinarians, and animal 
handlers. Travelers in high-risk areas should be vaccinated after a risk assessment. 
Children living in or visiting rabies-affected areas are at particular risk and should 
be given pre-exposure prophylaxis. One dose is given on each of days 0, 7, and 
21 or 28. Day 0 is the date of administration of the first dose of vaccine. Periodic 
booster doses of rabies vaccine are not necessary for people living in or travelling 
to high-risk areas who have received a complete primary series of pre- or post-
exposure prophylaxis. Only people whose occupation puts them at continual or 
frequent risk of exposure should receive periodic booster injections. If available, 
monitoring of rabies virus neutralizing antibody of personnel at risk is preferred 
to routine boosters. For people potentially at high risk of laboratory exposure to 
high concentrations of live rabies virus, a neutralizing antibody titration should be 
performed every 6 months. If the titer falls below 0.5 IU/ml of serum, one booster 
dose of vaccine should be given (Anonymous 2013).
Factors that should be taken into consideration in deciding to initiate post-
exposure prophylaxis include the epidemiological likelihood that the implicated 
animal was rabid, the severity of exposure, the clinical features of the animal, 
its vaccination status, and its availability for observation and laboratory testing. 
All exposures determined to represent a risk of rabies require post-exposure 
prophylaxis. Rabies immunoglobulin is administered only once, preferably at the 
same time or as soon as possible after the initiation of post-exposure vaccination. 
Vaccination regimens follow WHO’s recommended protocols and typically 
consist of multiple injections over a period of four weeks. In Finland, vaccination 
29
recommendations are given by the National Institute for Health and Welfare 
(Anonymous 2017b)
2.7.2 Dog-mediated rabies
The control of rabies in domestic dogs has important implications not just for the 
health of the dogs but also for public health. Each year, an estimated 7 million 
people are bitten by suspected rabid dogs. The most cost-effective way to eliminate 
human rabies is to eliminate dog rabies. In the 19th century, muzzling and dog 
movement restriction were used to control dog rabies. By the early 1900s, animal 
rabies vaccines had been developed. During the second half of the 20th century, dog 
rabies was eliminated through mass vaccination from Western Europe. Livestock 
deaths due to canine rabies are still poorly quantified, but are probably an important 
loss in impoverished livestock-dependent communities (Hampson et al. 2015).
Dog population management aims to stabilize or reduce the population size 
or density, adjust the population structure, improve the overall health, or alter 
the behavior of the dog population. Intervention includes culling and sterilization 
programs, sometimes combined with rabies vaccines. It is important to note that 
dog rabies can be very effectively controlled by vaccination programs alone (Knobel 
et al. 2013). Mass culling of dogs should not be an element of a rabies control 
strategy: it is ineffective and can be counterproductive to vaccination programs. 
Intensive information and education campaigns are needed to strengthen 
community support and volunteer engagement in order to increase dog vaccination 
and responsible pet ownership. Surveillance and diagnostic facilities need to be 
strengthened to include rapid diagnostic measures (Anonymous 2013).
2.7.3 Sylvatic wildlife rabies
Depopulation of foxes only results in a transient lull in the prevalence of rabies. 
Oral rabies vaccination of foxes and raccoon dogs has reduced rabies cases in 
Europe, and several countries are now free of rabies in wildlife (other than bats). 
Only concerted actions across borders will lead to the successful control of rabies 
(Anonymous 2015).
2.7.4 Bat-related rabies
Vaccination of free-living bats is not feasible and there is therefore no effective way 
to eradicate lyssaviruses from bats. Culling of bats is not appropriate considering 
their valuable role in the environment, but hematophagous bats have been culled 
in Latin America by the administration of anticoagulants. In Europe, bats are 
under legal protection and conservation (Council Directive 92/43/EEC on the 
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conservation of natural habitats and of wild fauna and flora 94/43/EEC and the 
Agreement on the conservation of populations of European bats). The spillover of 
lyssaviruses from bats to other mammals and humans can be managed. The impact 
of hematophagous bat-related rabies on cattle can be minimized by vaccinating 
the cattle (Barrett 2011). 
2.7.5 Surveillance of rabies
Surveillance involves the systematic continuous collection, analysis, and 
interpretation of data in order to demonstrate the absence of disease or to identify 
its presence and distribution based on the diagnostic confirmation of suspected 
and probable cases in humans and animals (Anonymous 2013). 
Several recommendations by international organizations have been made 
on rabies surveillance (EFSA, WHO, OIE, EU). Passive surveillance implies the 
detection of rabies in suspected cases without actively searching for a disease. To 
determine the real-time spatial and temporal distribution of rabies by specific virus 
variants, passive surveillance is inadequate. Active rabies surveillance is targeted 
and typically initiated by the investigator with a designed sampling scheme. 
2.7.6 Legislation concerning rabies surveillance and control 
In Finland, rabies in humans is a notifiable communicable disease according to the 
Ministry of Social Affairs and Health: Communicable Diseases Decree 146/2017. 
Rabies in animals is a notifiable disease according to the Act on Animal Diseases 
(441/2013). The measures for the control of rabies are provided in Decision No. 
724/2014 of the Veterinary and Food Department, including the investigation 
of all suspected cases by the veterinary authorities, notification procedures, and 
mandatory vaccination of hunting dogs and dogs used by officials. Dogs, cats, 
and ferrets entering Finland shall be vaccinated against rabies in accordance with 
Regulation No. 576/2013 of the European Parliament and of the Council.
2.8 Bats associated with lyssaviruses
Bats are the second most diverse group of mammals on Earth, with more than 1150 
species. One in five mammal species is a bat, and they are found on every major 
land mass except for the Polar Regions and a few islands. Bats are reservoirs of 
many potentially infectious agents, such as Ebola virus, Nipah virus, SARS-like 
coronavirus, and lyssaviruses (Barrett 2011).
About 70% of bat species are insectivores, while most of the rest are frugivores. 
A few hematophagous bat species feed on blood from animals. Lyssaviruses have 
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been detected in many of the bat species that have been surveyed and should be 
assumed to be present in all bat species globally. Many countries have conducted 
few or no surveys on bats, and data are very limited for African and Eurasian bats, 
as well as Indian and South-East Asian bats. For some lyssavirus species, only 
one or a few isolates are available (Barrett 2011). In Europe, circa 45 bat species 
are present and lyssaviruses have been identified from at least eleven different 
bat species.
2.8.1 Bats in Finland
In Finland, thirteen species of bats have been recorded. All of these, apart from 
the northern bat (Eptesicus nilssonii), are at the northernmost limit of their range. 
Most of the species are restricted to southern and central Finland. Only five bat 
species are common, and the rest are either very rare or only a few individuals 
have ever been seen (Table 2). The distribution ranges of bats in Finland are still 
poorly known due to the limited number of bat studies carried out in the country.
Daubenton’s bats are small, weighing about 5 to 15 g, and insectivorous. They 
are widespread and common in Finland. Daubenton’s bats hibernate from October 
till March or April. They are facultative seasonal migrants, covering middle-range 
distances of 100–150 km between summer and winter roosts, and the longest 
recorded distance covered is 257 km (Hutterer et al. 2005). However, Daubenton’s 
bats may show strong roost fidelity during the breeding season and between 
breeding seasons. Several studies have demonstrated that females in particular 
change their roost fairly often, every few days (Lucan et al. 2010). Fidelity is also 
apparent for larger areas with good feeding habitats and several roosting sites 
(Kapfer et al. 2008). Daubenton’s bats prefer to roost in abandoned woodpecker 
cavities and bird or bat boxes. The majority of the animals hunt over water or in 
the vicinity of waterways, but they also hunt in forests, parks, or meadows. They 
usually forage close to the roost, within a distance of one kilometer (Parsons et 
al. 2003). Daubenton’s bats are partially opportunistic trawling bats; insects are 
usually caught directly from the water surface.
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Table 2. Status and distribution of the bat species recorded in Finland, modified from Kyheröinen et 
al. 2010. Status categories for red-list species are based on Liukko et al. 2010.
Species in Latin Common name in 
English
Distribution in 
Finland
Status
Eptesicus nilssonii The northern bat Widespread in 
southern Lapland 
Common
Eptesicus serotinus Serotine bat Southern Finland Only a few records 
(first record in 2008)
Myotis brandtii  Brandt’s bat Widespread in 
southern and 
central Finland
Common
Myotis dasycneme Pond bat Eastern Finland Only a few records in 
Finland (first record 
2002)
Myotis daubentonii Daubenton’s bat Widespread in 
southern and 
central Finland
Common
Myotis mystacinus Whiskered bat Widespread in 
southern and 
central Finland
Common
Myotis nattereri Natterer’s bat Southern Finland Rare, endangered
Nyctalus noctula Common noctule Southern Finland Rare, migrant
Pipistrellus nathusii Nathusius pipistrelle Southern Finland Restricted, migrant
Pipistrellus pipistrellus Common pipistrelle Southern Finland Rare migrant (first 
record 2001)
Pipistrellus pygmaeus Soprano pipistrelle Southern Finland Rare, migrant (first 
record 2007)
Plecotus auritus Common long-eared bat Southern and 
Central Finland
Common, widespread
Vespertilio murinus Parti-colored bat Southern Finland Rare, migrant
2.9 Laboratory diagnosis of lyssaviruses
Because the signs of rabies may vary, laboratory diagnosis of the suspected animal 
is essential. Reliable diagnosis of rabies in animals might save human lives. A 
positive result leads to a public health investigation and post-exposure treatment 
of people, as well as to control measures to prevent the further spread of rabies 
within the animal population. A negative result may rule out the need for post-
exposure treatment of humans and the management of domestic exposed animals 
(Hanlon and Nadin-Davis 2012).
Rabies diagnosis in animals is post-mortem diagnosis. The virus, viral genome or 
antigen can be detected in a brain sample. Serology can be used to detect antibodies 
due to rabies vaccination. Seroconversion due to natural infection only happens 
in the late gestation of the disease with advanced clinical signs, if at all, and is not 
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therefore a useful tool for demonstrating natural infection in animals other than 
bats. For bats, saliva swabs can be used to detect lyssaviruses or viral genome from 
live bats. Ante-mortem diagnosis is possible during the clinical human disease. 
The best samples are skin biopsy from the nape of the neck, saliva, serum, or 
cerebrospinal fluid (Anonymous 1996, 2015).
2.9.1 Detection of the virus
The direct fluorescent antibody test (FAT) is a rapid, sensitive, and specific method 
for diagnosing rabies and it is the gold standard method. The test is based on the 
microscopic examination of impressions or smears of brain tissue after incubation 
with anti-rabies globulin or antibodies conjugated with fluorescein isothiocyanate. 
Immunoperoxidase methods can be used as an alternative to FAT. An ELISA 
that detects rabies antigen is a variation of the immunochemical test. A rapid 
immunodiagnostic test (RIDT) can be used under field conditions and in developing 
countries with limited diagnostic resources.
Detection of the replicating virus after inoculation of a tissue suspension in cell 
cultures (RTCIT) or in laboratory animals shows the infectivity of the virus. Various 
molecular diagnostic tests, e.g. the detection of viral RNA by reverse transcription 
PCR (RT-PCR), PCR-ELISA, in situ hybridization, and real-time PCR, are used 
as rapid and sensitive additional techniques for rabies diagnosis. They are useful 
for confirmatory diagnosis as a first step in virus typing followed by sequencing 
(Anonymous 1996, 2015).
2.9.2 Detecting rabies antibodies
The main application of serology for rabies is to determine the response to vaccination 
in domestic animals prior to international travel, in wildlife populations following 
oral immunization, and for people after vaccination. For bats, seropositivity can 
be used as a tool to detect natural or experimental infection with lyssaviruses.
As neutralizing antibodies are considered a key component of the adaptive 
immune response against rabies virus, the gold standard tests are virus 
neutralization (VN) tests: the fluorescent antibody virus neutralization (FAVN) 
test and the rapid fluorescent focus inhibition test (RFFIT). Indirect ELISAs have 
been developed that do not require high-containment facilities and produce rapid 
results (Anonymous 1996, 2015).
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2.10 Potency tests of vaccines
Varying requirements relating to quality, safety, and efficacy apply for manufacturers 
to obtain authorization or a license for a vaccine. The potency of inactivated virus 
vaccines is established and controlled using tests formulated by the European 
Pharmacopoeia. For live vaccines that are prepared for oral vaccination of animals, 
safety and efficacy in the target animals and safety in non-target species must be 
demonstrated (Anonymous 1996, 2015).
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3 AIMS OF THE STUDY
This study was conducted to investigate the epidemiology of the EBLV-2 in Finland, 
to characterize the EBLV-2 viruses, and to assess the efficacy of vaccination against 
EBLV-2. 
The specific aims of this study were as follows:
1. To study the epidemiology of EBLVs in Finnish bat populations (I) and to 
gain a better understanding of the public health risk that EBLV-infected bats 
pose (I, III, IV).
2. To describe the phylogenetic analysis of Finnish EBLV-2 strains isolated from 
a human in 1985 and from diseased bats in 2009 and 2016 (II, IV).
3. To calculate the tempo of viral evolution and divergence times for EBLV-2 
viruses by molecular-clock estimation (II).
4. To assess the efficacy of animal and human vaccines against challenge with 
EBLV-2 isolated from a bat in Finland in comparison to challenge with RABV 
isolated from a raccoon dog (III).
5. To assess the factors influencing the success of rabies vaccination of the dog 
and cat population in Finland (III).
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4 MATERIALS AND METHODS
4.1 Active and passive surveillance of bats (I, IV)
Dead bats or bats euthanized after showing clinical signs of rabies have been 
submitted to Evira for autopsy and laboratory analysis by veterinarians, members 
of the public, animal shelters, and bat biologists. The number of bats tested during 
1985–2016 was 331, and details are presented in Table 5. Active surveillance 
took place in 2010–2011. Bats of seven bat species (Table 6) were caught from 71 
sampling sites. Capture was carried out using a combination of harp traps and mist 
nets. Daubenton’s bat roosts were primarily sampled. Samples were also collected 
from an old mill at a single site. Most of the samples were taken in southwest 
Finland, from Hamina in the east to Turku in the west.
Saliva samples were collected from 459 and 315 bats in 2010 and 2011, 
respectively. The specimens were collected from the oral cavity and oropharynx 
using dry nylon fiber- tipped oral swabs (Copan) and transported in a Copan 
Universal Transport Medium (UTM-RT) System (Copan Diagnostics Inc.). They 
were kept frozen until laboratory analysis.
Blood samples were collected from a total of 423 bats of six different species 
(Table 6). Blood samples were collected from 275 and 148 bats in 2010 and 
2011, respectively. Sera were collected into a single 75-μl capillary tube from the 
interfemoral vein after lancing with a 27-gauge needle. The capillary tubes were 
centrifuged. Serum for rabies antibody screening was stored in Eppendorf tubes, 
which were kept frozen at -20 °C until laboratory analysis.
4.2 Laboratory analysis (I, II, III, IV)
4.2.1 Antigen detection (I, II, III, IV)
Rabies laboratory diagnosis was performed on brain samples according to the 
OIE Manual of Standards for Diagnostic Tests and Vaccines, using a standard 
fluorescent antibody test (FAT). Smears prepared from a sample of brain tissue 
were fixed in high-grade cold acetone, air dried, and then stained with specific 
conjugate. Two conjugates were used: rabies conjugate anti-nucleocapsid (Bio-
Rad, USA) and FITC anti-rabies monoclonal globulin (Fujirebio Diagnostics Inc., 
USA), which were diluted according to the manufacturers’ instructions. FAT slides 
were then examined for specific fluorescence using a fluorescence microscope.
37
4.2.2 Virus isolation (II, III, IV)
Virus isolation was performed in mouse neuroblast cell culture, according to a 
procedure described in the OIE manual. In addition, the bat brain suspension of 
the 2009 isolate was inoculated into suckling mice. Eight newborn mice (ScaNmri) 
at 2 days old were intracerebrally infected with 20 µl of the suspension in the 
Biosafety Level 3 (BSL-3) laboratory. When the mice started to develop signs of 
encephalitis, they were euthanized and the brains were collected and examined 
using a fluorescence antibody test (FAT) for the presence of lyssavirus. The human 
virus isolate of 1985 (Lumio et al. 1986, Roine et al. 1988) used in this study was 
the first archived newborn mouse passage, and had been kept at -70 °C since 1986.
4.2.3 Nucleic acid detection (I, II, IV)
The RNA for PCR studies was extracted from the samples with a QIAamp Viral RNA 
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
RNA was tested for reaction EBLV-1 and EBLV-2 (I) with the OneStep real-time 
reverse transcription-polymerase chain test (OneStep RT-PCR kit, Qiagen, Hilden, 
Germany). The reaction volume was 50 µl and the temperature profile of cDNA 
synthesis and amplification was: 50 °C for 30 min, 95 °C for 15 min, and 45 
cycles of 95 °C for 30 s, 52 °C for 30 s, and 72 °C for 20 s. The sequences for the 
primer (JW12, N165-146) and the probe (LysGT5 and LysGT6) were published 
by Wakeley et al. (2005).
Primers for whole genome sequencing (II) were designed with the program 
PCR Suite (van Baren 2004) and modified afterwards, if needed. The OneStep RT-
PCR kit (Qiagen, Germany, Hilden) was used to amplify 34 overlapping fragments. 
The following thermal profile was used: a single cycle of reverse transcription for 
30 min at 50 °C, 15 min at 94 °C for reverse transcriptase inactivation and DNA 
polymerase activation, followed by 30 amplification cycles of 1 min at 94 °C, 1 min 
at 50 °C, and 1 min at 72 °C. 
For the bat sample of 2016 (IV), the OneStep RT-PCR kit (Qiagen, Germany, 
Hilden) was used to amplify two fragments. The reaction volume was 25 µl and 
the temperature profile of cDNA synthesis and amplification was 30 min at 50 
°C, 15 min at 94 °C for reverse transcriptase inactivation and DNA polymerase 
activation, followed by 30 amplification cycles of 1 min at 94 °C, 1 min at 50 °C, 
and 1 min at 72 °C. Primers (N127, N66CS, N512 and N8m) were published by 
Davis et al. (2005).
All the primers used are presented in Table 3.
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Table 3. Primers and probes used in the RT-PCR and sequencing. Primer and probe positions by 
Wakeley et al. (2005) are given relative to the Pasteur virus genome (accession no. M13215). The position 
numbering by Jakava-Viljanen et al. (2015) is according to the EBLV-2 isolate RV1333 (EF157977). 
Sequence positions by Davis et al. (2005) are numbered relative to the rabies virus PV genome.
References: 1. Wakeley et al. (2005), 2. Jakava-Viljanen et al. (2015), 3. Davis et al. (2005).
Primer Sequence 5’-3’ Position Reference
N165-146 gca ggg tay ttr tac tca ta 165–146 1
JW12 atg taa cac cyc tac aat g 55–73 1
1f acg ctt aac gac aaa acc ag       1–20 2
1r tag ctc tcc caa tcg tca gg   326–345 2
2f cgc tag gtt gga tcc tga tg   256–275 2
2r ggc gca cat ctt gtg agt ag   636–655 2
3f cca acg tag ctg aca gaa tgg   558–578 2
3r aca tct cgt gag gtg cac ag 1066–1085 2
4f cgg gag tta cat ggg tca ag 1015–1034 2
4r gtc tgg cct gat gat tcg ag 1354–1373 2
5f cag gat cat ggt caa tgg 1291–1308 2
5r tcc caa cac cct caa ggt ag 1812–1831 2
6f aag aag aag gaa gcg atg agg 1745–1765 2
6r tgc gct att tct gct tca ac 2116–2135 2
7f acc tgc gct gga atg gtc 2070–2087 2
7r ggg agc cat agg tca tca tc 2591–2610 2
8f agt gag agg ttg cag gga tg 2530–2549 2
8r act ctg ccc att gaa aca cc 2869–2888 2
9f ttc cag agg gaa tga act gg 2826–2845 2
9r ggt gtt cag tcg ggt gtt tc 3245–3264 2
10f ctt tta tga gca ata gaa caa aac c 3186–3210 2
10r atg tcg gat cac ctg cag tc 3688–3704 2
11f aac tac cac gtt caa gag aaa gc 3619–3641 2
11r ttt gcc tca tcg tga ttt tg 4115–4134 2
12f tga aac tgt gtg gaa tct ctg g 4059–4080 2
12r atg ctg ttg aag cat tgc ag 4518–4537 2
13f tcc tca tca caa tgg agt ctt c 4441–4462 2
13r ccc act ttg gga agt gac ag 4830–4849 2
14f aaa gag agc caa acc caa cc 4787–4805 2
14r att gca tcc tct ccc act tg 5154–5171 2
15f acc ggt aca cag ggt ctt gc 5076–5095 2
15r gca tct atc tcc ggt tcg ac 5458–5477 2
16f aga tga ttg atc ccc tgg ag 5414–5433 2
16r gag gca ctt tcg act tct gg 5747–5766 2
17f cgc aca atc cat gat gtc tc 5697–5716 2
17r gaa tca gga ggg agt tga acc 6173–6193 2
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18f tct cag agt gcc aac tgt ctg 6106–6126 2
18r gtt cct tca agc tgg ctc ac 6415–6434 2
19f tta gtg cag agg gct gaa gg 6340–6359 2
19r tat ggg atc aaa ggg tgg tc 6709–6728 2
20f ctg gct aaa cgg atc ctc ag 6634–6653 2
20r aag aat tcc ctg ggg ttg ac 6964–6983 2
21f ccg tcc cca gtg aga aag tc 6917–6936 2
21r gac ctt gtc ccg tga ctc tg 7209–7228 2
22f ttg gcg aac tac atc tta ccc 7129–7149 2
22r tga gtc cct ctt ggg tca ac 7641–7660 2
23f agc aca ggg aga caa cca ag 7590–7609 2
23r gtg aaa tac cgc ctg gac tg 7979–7998 2
24f gtc gca cag cat tca caa tc 7924–7943 2
24r agc aga atg gtt gga ctt gc 8332–8351 2
25f ccg gac ttg ggt gat aga ag 8254–8273 2
25r aaa ttg ccg tcg aat tgt tc 8567–8586 2
26f gct cat cct tcc tcg gaa tac 8513–8533 2
26r gat ttg agt ccc tgg caa tg 9021–9040 2
27f cca acg tcc atg ttg tca ag 8966–8985 2
27r aga cat ccg gga aca tga ag 9417–9436 2
28f caa gtg cat ccg acc gat ag 9369–9388 2
28r cag atc gaa gtg agg gtt cc 9831–9850 2
29f tgt tga ggc tag aca atc atc c 9788–9809 2
29r taa ggt gtc ttc ccc gtg ac 10151–10167 2
30f atc cga ctc agg cag ttg ag 10105–10124 2
30r gag gcc atg agg tca ttc ac 10606–10625 2
31f tgg aat ctc cag aac tgt gc 10539–10558 2
31r tgg cct tgt agt ctg ggt tc 10923–10942 2
32f ctc tcg atc aat ggt cca ctc 10867–10887 2
32r tta gcc aag gtc cct ctt tg 11287–11306 2
33f tga agt cga gtc att cct agt cc 11238–11260 2
33r gct act acc ggc aag tcg ag 11672–11691 2
34f aag caa gtc ata cga gga ag 11533–11552 2
34r acg ctt aac aaa aaa aac ata g 11909–11930 2
N127 atg taa cac ctc tac aat gg 55–74 3
N66CS gtg ctc car ttt gcr cac a 578–596 3
N512 gtg gcw gay aga atg gaa ca 493–512 3
N8m cag tct cyt cng cca tct c 1567–1586 3
Probes
LysGT5 aac arg gtt gtt tty aag gtc cat aa 80–105 1
LysGT6 aca raa ttg tct tca arg tcc ata atc ag 81–109 1
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Table 4. Lyssavirus strains used in the phylogenetic studies.
Species Abbrevi-
ation
Country Host Year Accession 
number
Reference
European bat 
lyssavirus 2
EBLV-2 Finland Homo 
sapiens
1985 JX129233 II
European bat 
lyssavirus 2
EBLV-2 Finland Myotis 
daubentonii
2009 JX129232 II
European bat 
lyssavirus 2
EBLV-2 Finland Myotis 
daubentonii
2016 MF326269 IV
European bat 
lyssavirus 2
EBLV-2 Netherlands Myotis 
dasycneme
1987 U89480 Amengual B. J. Gen Virol 78 
(Pt 9), 2319-2328 (1997)
European bat 
lyssavirus 2
EBLV-2 Netherlands Myotis 
dasycneme
1989 AY062089 Johnson N. Arch Virol 147 (11), 
2111-2123 (2002)
European bat 
lyssavirus 2
EBLV-2 Netherlands Myotis 
dasycneme
1986 EU293114 Delmas O. PLoS ONE 3 (4), 
E2057 (2008)
European bat 
lyssavirus 2
EBLV-2 Netherlands Myotis 
dasycneme
1993 AY863404 Davis P. J Virol 79 (16),
10487-10497 (2005)
European bat 
lyssavirus 2
EBLV-2 Switzerland Myotis 
daubentonii
1992 AY212117 Johnson N. Vet Rec 152 (13), 
383-387 (2003)
European bat 
lyssavirus 2
EBLV-2 Switzerland Myotis 
daubentonii
1993 U89479 Amengual B. J Ge. Virol 78 (Pt 9), 
2319-2328 (1997)
European bat 
lyssavirus 2
EBLV-2 Switzerland Myotis 
daubentonii
1993 AY212118 Johnson N. Vet Rec 152 (13), 
383-387 (2003)
European bat 
lyssavirus 2
EBLV-2 Switzerland NA 2002 AY863408 Davis, P. J Virol 79 (16), 
10487-10497 (2005)
European bat 
lyssavirus 2
EBLV-3 Switzerland Myotis 
daubentonii
2002 KF831571 Deubelbeiss AN. Unpublished
European bat 
lyssavirus 2
EBLV-2 Germany Myotis 
daubentonii
2006 JQ796805 McElhinney L. Zoonoses Public 
Health 60 (1), 35-45 (2013)
European bat 
lyssavirus 2
EBLV-2 Germany Myotis 
daubentonii
2007 GU227648 Freuling C. Vet Microbiol 131 (1-2), 
26-34 (2008)
European bat 
lyssavirus 2
EBLV-3 Germany Myotis 
daubentonii
2013 KF826149 Schatz J. PLoS Negl Trop Dis 8 
(5), E2835 (2014)
European bat 
lyssavirus 2
EBLV-2 United 
Kingdom
Myotis 
daubentonii
1996 U89478 Amengual B. J Gen Virol 78 
(Pt 9), 2319-2328 (1997)
European bat 
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EBLV-2 United 
Kingdom
Homo 
sapiens
2002 EF157977 Marston DA. J Gen Virol 88 
(PT 4), 1302-1314 (2007)
European bat 
lyssavirus 2
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444 (2013)
Gannowuwa 
bat lyssavirus
GBLV Sri Lanka Pteropus 
giganteus
2015 KU244269 Gunawardena PS. Emerging Infect 
Dis 22 (8), 1456-1459 (2016)
42
After agarose gel electrophoresis, the bands were cut from the gel and DNA 
was extracted with the Qiaquick Gel Extraction Kit (Qiagen, Germany, Hilden). 
PCR products were sequenced using an ABI 3100 Avant Genetic Analyzer (Applied 
Biosystems) with the primers used in the PCR and a Big Dye Terminator v3.1 Cycle 
sequencing kit (Applied Biosystems). Before sequencing, the reaction products were 
purified using the DyeEx 2.0 Spin Kit (Qiagen, Germany, Hilden). The sequences 
were analyzed with Sequencing Analysis software version 6.0 (Applied Biosystems).
The newly obtained genome sequences (GenBank accession numbers JX129232, 
JX129233 and MF326269) were aligned with other published lyssavirus bat-type 
isolates extracted from GenBank to evaluate the genetic diversity of EBLV-2 strains 
and their relationship with other bat-associated genotypes. Amino acid sequences 
were deduced using the “translate” function of the program MEGA v.5.1 (Tamura et 
al. 2011). Phylogenetic trees of full-length genomes and partial N coding sequences 
were calculated using the maximum likelihood approach in the program MEGA 
with 1000 bootstrap replicates. The pairwise sequence identities were calculated 
using CLUSTAL W2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/), with default 
settings. The lyssavirus strains used in these phylogenetic analyses are presented 
in Table 4.
For evolutionary time-scale analysis (II), the program BEAST (Drummond 
et al. 2007) was used to estimate the substitution rate of EBLV-2 and time of 
divergence from the phylogenetically closest lyssavirus species. The data set used 
for estimating the rate of evolution was based on the partial N coding sequences 
(400 bp) of EBLV-2 strains isolated from the years 1986 to 2012. The Hasegawa-
Kishino-Yano (HKY) model of nucleotide substitution was used (Hasegawa et 
al. 1985), and both strict and relaxed lognormal clock models. Convergence of 
parameters was assessed using TRACER (Drummond et al. 2007), and each run was 
continued until the effective sampling size of all parameters was greater than 200.
4.2.4 Serological analysis (I, III)
Serological testing for EBLV virus neutralizing antibodies from bat samples was 
performed using a fluorescent antibody virus neutralization test (Cliquet et al. 
1998) according to modification (mFAVN) by the UK Animal Health and Veterinary 
Laboratories Agency (AHVLA). The volume of sera used was 30 µl. The EBLV-2 
antigen, strain RV 628, was provided by the European Virus Archive supported 
by the European Community. Two positive control sera, both provided by the 
European Virus Archive, were used in each test. Samples needed to be pooled to 
obtain the minimum serum volume required for the test. In total, 167 pools were 
tested. Samples from animals of the same species, gender, and site were pooled. 
Samples were analyzed in duplicate and serially diluted using a 3-fold series. A 
titer of 1:27 was chosen to distinguish positive from negative samples. 
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The serum samples of the vaccinated mice were analyzed using the rapid 
fluorescent focus inhibition test RFFIT (OIE). Serial dilutions of test sera were 
mixed with the challenge virus preparation and BHK-21 cells. Samples were fixed 
and stained with specific conjugate (FITC Anti-Rabies Monoclonal Globulin, 
Fujirebio Diagnostics). Residual virus was detected using a standard fluorescence 
microscope. The serum neutralization end-point titer was defined as the dilution 
factor of the highest serum dilution at which 50% of the observed microscopic 
fields contained one or more infected cells.
The antibody responses of dogs and cats were determined using the FAVN test 
(Cliquet et al. 1998). This test involves the neutralization of a constant amount of 
rabies virus CVS-11 strain adapted to cell culture before inoculating cells susceptible 
to rabies virus (BHK-21). The serum titer is the dilution at which 100% of the virus 
is neutralized in 50% of the wells. This titer is expressed in IU/ml by comparing 
it with the neutralizing dilution of OIE serum of dog origin under the same test 
conditions. Dogs and cats with titers of ≥0.5 IU/ml had passed the test and dogs 
with titers of <0.5 IU/ml had failed the test. 
4.3 Vaccination challenge of mice with RABV and EBLV-2  
 after vaccination with a human vaccine and an animal  
 vaccine (III)
Three- to four-week-old NMRI mice (Harlan, NL; n = 20 per challenge virus and 
n = 5 vaccine controls) were vaccinated intra-peritoneally with 0.1 ml of vaccine 
diluted 1:10 in physiological saline solution with a 16-mm needle. With the human 
vaccine (Rabies-Imovax®; Sanofi-Pasteur MSD, France, batch G1391-4), the mice 
were vaccinated either once or twice with a two-week interval. With the animal 
vaccine (Rabisin® vet; Merial, France, batch L374051), the mice were vaccinated 
once. Vaccines were purchased from Helsinki University Pharmacy.
The potency test protocol was modified from the European Pharmacopoeia 
protocol: the minimum lethal dose (MLD50) for the intra-cranial challenge was 
determined and the 50 MLD50 was used, and mice were challenged intra-cranially 
with 30 µl of 10% virus suspension according to the procedure described by WHO 
(Anonymous 1996) 28 days after vaccination. The suspension was prepared with 
MEM and later with physiological saline. The mice were anesthetized by inhalation 
anesthesia using isoflurane and were given 0.05–0.1 mg/kg buprenorphine 
hydrochloride subcutaneously at the time of intra-cranial challenge. The back 
titration of 5 mice per group was set up with 50 MLD50, 5 MLD50 and 0.5 MLD50 
of each virus. Five mice per vaccine that were not challenged served as vaccine 
controls. The mice were monitored twice per day for any clinical signs of rabies, 
and to minimize suffering they were killed when signs of rabies infection were 
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obvious (weight loss, behavioral changes, neurological signs, and paralysis) or 
when the observation period of six weeks had ended. Serum was collected from 
the vaccinated mice prior to the challenge, approximately three weeks after the 
vaccination. At the end of the trial, the brains and sera of the mice were collected 
either at the time they were euthanized due to rabies signs or when they were 
euthanized after the monitoring period. 
4.4 Post-vaccination analysis of dog and cat samples (III)
This was a case-control study with a duration of five years. During 2009–2013, 
serum samples from dogs (n = 10 071) and cats (n = 722) were sent to the Finnish 
Food Safety Authority Evira for post-vaccination efficacy tests. Of these samples, 
1055 dogs that did not pass the test and had submission data available comprised 
the case group for dogs. An approximately similar number of dogs with submission 
data that passed the test were randomly assigned to the control group (n = 1626). 
In cats, only 25 failed the test (cases) and a much larger number of cats that passed 
were randomly assigned to the control group (n = 241). Submission forms for these 
samples were evaluated. Three (3) inactivated rabies vaccines were used for dogs 
and cats in Finland during 2009–2013: Wistar-G52 strain vaccine, BHK-21cell 
vaccine with Pasteur RIV strain, and Flury LEP strain vaccine.
4.4.1 Statistical analysis (III)
The 95% confidence intervals (CI) for valid percentages (excluding missing 
values) were calculated with Jeffrey’s method using EpiTools (Sergeant 2015). 
Statistical analyses were performed using the statistical software SPSS 22.0 (IBM 
SPSS Statistical Package version 22, USA). The outcome variable was failure to 
reach the required antibody level (0 for antibody level ≥0.5 IU/ml, denoting 
the ability to reach the required antibody level, and 1 for <0.5 IU/ml, denoting 
failure). Independent variables collated in the dataset were the vaccine used, age 
at vaccination, gender, the number of vaccinations, and the time from vaccination 
to sampling, and for dogs, the breed and height of the dog as measured at the 
withers. Dogs were categorized into five different breed size groups based on their 
height (<30 cm, 30–45 cm, 46–60 cm, >60 cm, and unknown). 
Animals were divided into two age groups: up to one year and over one year old. 
Based on the time interval between vaccination and sampling, three groups were 
created: sampling less than three months after vaccination, three to six months 
after vaccination, and more than six months after vaccination. First, Fisher’s exact 
test and crude logistic regression analyses were performed to examine the pairwise 
associations between the outcome and each independent variable separately. 
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Variables with p ≤ 0.2 were included in the multivariable logistic regression 
analysis, with separate models for cats and dogs, and variables with Wald’s p < 
0.05 were included in the final model. Correlations between independent variables 
were calculated with Spearman’s test and no significant correlations were found. A 
causal diagram was used to assess potential confounders; their impacts on the other 
variables in the model were verified, but none needed to be included in the models. 
Pairwise interactions were assessed. Since in dogs a significant interaction was 
found between the vaccine used and the age of the dog, two separate models were 
created: one for dogs up to one year old and another for older dogs. Additionally, for 
younger dogs, the time interval between vaccination and sampling was categorized 
into two groups only: up to or more than six months. The goodness of fit of the 
final model was assessed with the Omnibus test, Nagelkerke’s R2, and the Hosmer 
and Lemeshow test, and by calculating the area under the curve (AUC).
4.5 Ethical approval and permissions (I, III)
The National Animal Experiment Board of the County Administrative Board 
of Southern Finland approved the sampling of bats, including blood and saliva 
sampling (permit numbers: Lilley ESLH-YM-2007-01055, Kyheröinen ESLH-2009-
04958/Ym-23), which followed Finnish legislation, namely the Finnish Act on the 
Use of Animals for Experimental Purposes (62/2006). Bats were captured and 
handled under permits from the following regional environmental centers (Centre 
for Economic Development, Transport and the Environment): Southeast region, 
KASELY/379/20/07.01/2010; Southern Finland, LUO 459/UUS-2009-L-388-254 
and UUDELY/475/07.01/2011; Southwest region, LOS-2007-L-182-254; and 
Eastern region, POSELY/501/07.01/2010 and ESAELY/557/07.01/2010.
The National Animal Experiment Board of the County Administrative Board 
of Southern Finland approved the diagnostic mouse inoculation test (permission 
number ESLH-2008-06899/Ym-23).
The vaccination challenge was carried out with the permission of the National 
Animal Experiment Board of the County Administrative Board of Southern Finland 
(permission number ESAVI-2010-06673/Ym-23 and ESAVI/955/04.10.07/2013), 
which followed the Finnish Act on the Use of Animals for Experimental Purposes 
(62/2006).
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5 RESULTS
5.1 Passive and active surveillance of the bats (I, IV)
In the passive surveillance of 331 samples during 1985–2016 (Table 5), two positive 
Daubenton’s bat were detected by FAT, RTCIT (Fig. 6), and by RT-PCR and 
subsequent sequencing: one in 2009 and the other in 2016. The 2016 Daubenton’s 
bat was a cachexic adult female, weighing 7 g. Only 15 Daubenton’s bats were 
submitted for laboratory analysis, and two were positive for EBLV-2, which would 
indicate that 13% (95% Cl 3.7–38%) of all passive surveillance Daubenton’s bat 
were positive for EBLV-2 in Finland.
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Figure 6. RTCIT image of the 2016 Daubenton’s bat (A) and positive control (B) 
 
 
Table 5. Number of bats tested for rabies in the passive surveillance in Finland 1985–2016. 
 
Year Unknown/
N.A. 
Eptesicus 
nilssonii 
Myotis 
daubentonii 
Myotis 
mystacinus 
Myotis 
brandtii 
Plecotus 
auritus 
In total Number of  
positive samples 
2016  9 2 4 3 1 19 1 
2015 4 13 3 6   26 0 
2014 2 11  1   14 0 
2013 3 7  3  1 14 0 
2012 8 16 1 6  1 32 0 
2011 3 6  4   13 0 
2010  6 1 1   8 0 
2009 4 13 3 2  2 24 1 
2008       0 0 
2007 1 2     3 0 
2006  1     1 0 
2005   1    1 0 
2004  1  2  1 4 0 
2003   1    1 0 
Figure 6. RTCIT image of the 2016 Daubenton’s bat (A) and positive control (B)
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Table 5. Number of bats tested for rabies in the passive surveillance in Finland 1985–2016.
Year Unknown/
N.A.
Eptesicus 
nilssonii
Myotis 
daubentonii
Myotis 
mystacinus
Myotis 
brandtii
Plecotus 
auritus
In total Number 
of 
positive 
samples
2016 9 2 4 3 1 19 1
2015 4 13 3 6 26 0
2014 2 11 1 14 0
2013 3 7 3 1 14 0
2012 8 16 1 6 1 32 0
2011 3 6 4 13 0
2010 6 1 1 8 0
2009 4 13 3 2 2 24 1
2008 0 0
2007 1 2 3 0
2006 1 1 0
2005 1 1 0
2004 1 2 1 4 0
2003 1 1 0
2002 3 3 0
2001 1 1 0
2000 2 2 0
1999 2 2 0
1998 9 9 0
1997 1 1 0
1996 5 5 0
1995 5 5 0
1994 2 2 0
1993 1 1 2 0
1992 3 6 1 3 1 14 0
1991 5 5 0
1990 4 3 7 0
1989 3 3 6 0
1988 13 13 0
1987 35 35 0
1986 3 33 2 1 8 14 61 0
1985 1 1 0
In total 109 145 15 33 11 21 331 2
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Figure 7. The EBLV-2-in’fected Daubenton’s bat appearing in the day. (Photo: Riitta Räisänen)
Antibodies were detected from Daubenton’s bats from two sampling sites in 2010, 
in the city of Turku (60°27′05″N, 022°16′00″E) and in Nauvo (60°11′35″N, 
21°54′25″E), and from one sampling site in 2011 in the city of Naantali (60°28′05″N, 
22°01′35″E). No EBLV RNA was detected in the active surveillance in any of the 
oropharyngeal swabs analyzed (Table 6).
The seropositive samples were from 3 to 9 (due to the pooling of samples) male 
Daubenton’s bats. In the pool collected in 2010 from Turku, all individuals were 
adults and caught while flying. In the pool collected in Nauvo, all bats were adults 
and they were caught in roosts. In the seropositive pool collected in 2011 from 
Naantali, one individual was an adult and two were juveniles, and they were 
caught while flying. Altogether, 268 samples from Daubenton’s bat were analyzed, 
resulting in a seroprevalence of 1.12% to 3.36%. A 95% confidence interval for 
the true prevalence of 0.2–4% was calculated, as described by Rogan and Gladen 
(1978). All the positive sites were from the same geographical area (Fig. 8).  
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Table 6. Number of bats tested for cross-neutralizing lyssavirus antibodies and viral EBLV-1 and -2 per 
species, and number of positive bats during active sampling in 2010 and 2011.
Species Number of bats (number of 
positive bats) tested for lyssavirus 
antibodies
Number of bats (number of positive 
bats) tested for EBLV-1 and -2 RNA
M. daubentonii 268 (3–9*) 399 (0)
M. brandtii 71 (0) 129 (0)
P. auritus 38 (0) 98 (0)
E. nilssonii 29 (0) 108 (0)
M. mystacinus 16 (0) 36 (0)
M. nattereri 1 (0) 1 (0)
P.  nathusii 0 3 (0)
Total 423 (3–9*) (0)
* Pooled samples
Figure 8. Geographical locations of the lyssavirus antibody-positive Daubenton’s bats sample collection 
sites and the locations where two EBLV-2-positive Daubenton’s bats were found. Map: Pia Vilen.
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5.2 Virus isolation of the EBLV-2 strains 2009 and 2016  
 (II, IV)
Inoculation of the bat brain samples of 2009 and 2016 into MNA cells revealed 
the presence of virus in a limited number of cells after 3 days of incubation. In 
addition to the brain sample, several organs were tested for the 2016 Daubenton’s 
bat. The MNA cell culture was positive for the 2016 isolate from the brain, spinal 
cord, and salivary glands (Table 7).
Table 7. Results of lyssavirus detection from dierent organ and swab samples from the 2016 Daubenton’s 
bat. (FAT = fluorescent antibody test, RTCIT = rabies tissue culture infectious test, NA = not applicable)
Brain Spinal 
cord
Salivary 
gland
Mouth 
swab
Anal 
swab
Tongue Intestines Liver Eye Lung Trachea Bladder Tonsils
FAT + + NA NA NA NA NA NA NA NA NA NA NA
RTCIT + + + - - - - - - - - - -
RT-PCR + + + - - - - - - - - - -
The brain suspension of the 2009 bat isolate was inoculated into suckling mice. 
The mice began to develop signs of encephalitis on day 12 p.i. By day 17 p.i., all 8 
inoculated mice were euthanized. The presence of the virus in all the brain samples 
was confirmed by FAT. 
5.3 Genetic characterization and evolutionary time-scale 
analysis of the EBLV-2 strains from a human case in 1985 and 
from a bat in 2009 (II)
The complete lengths of the EBLV-2 1985 (GenBank accession number JX129233) 
and 2009 (GenBank accession number JX129232) genomes were 11 928 and 11 
927 nucleotides, respectively. Twenty nucleotides at the 5’ end and 22 nucleotides 
at the 3’ end of the genomes were primer derived and were excluded from all the 
phylogenetic analyses. 
The general genome organization was typical for lyssaviruses, consisting of five 
structural genes, N, P, M, G, and L, and non-coding regions between them and 
at both ends of the genome. The lengths of the genes and the number of deduced 
amino acids (in parentheses) were 1356 (451 aa), 894 (297 aa), 609 (202 aa), 1575 
(524 aa), and 6384 (2127 aa), respectively. The long untranslated region between 
the G and L genes was the only area that varied in length between the two Finnish 
EBLV-2 strains, being 510 bp in FI-85 and 509 bp in FI-09. The corresponding 
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lengths for other completely sequenced EBLV-2 strains were 511 bp for EU293114 
and 512 bp for KF155004 and EF157977.
The nucleotide identity between EBLV-2 1985 and 2009 strains was 99.6%. 
There were four amino acid differences between the two Finnish strains: N gene ah 
106 (N><S), G gene aa 158 (V><A), L gene aa 154 (R><K), and aa 1656 (G><D). 
The N, P, M, G, and L genes of the FI-85 and FI-09 strains shared 98–99%, 
98%, 99–100%, 97–99%, and 99% amino acid identity, respectively, with the 
previously published EBLV-2 strains. The non-coding regions were found to be 
highly divergent, yet rather similar for all EBLV-2 strains.
A phylogenetic tree was calculated based on the two novel EBLV-2 genomes and 
full-length bat-related lyssavirus genomes obtained from GenBank (Fig. 9). The 
analysis revealed that all five EBLV-2 strains are monophyletic. The phylogenetic 
tree also demonstrated that EBLV-2 strains share the most recent common ancestry 
with BBLV and KHUV, and more distant ancestry with ARAV, RABV and ABLV. 
A second major cluster of lyssaviruses consists of IRKV, DUVV, and EBLV-1. The 
clearly most divergent group is formed by WCBV. IKOV, LBV, SHIV, and MOKV.
In order to include more EBLV-2 strains, we calculated phylogenetic trees (Fig. 
10) based on partial N gene sequences. EBLV-2 strains were also monophyletic in 
this region. Some discrepancies were observed between the two trees, especially in 
the composition of the major clusters that were not reproduced in the phylogeny 
based on partial N-gene sequences.
The substitution rate of European bat lyssavirus type 2 was estimated using 
the two Finnish strains isolated 24 years apart as a calibrator. The overall rate was 
7.67 x 10-5 substitutions per site per year. The current diversity of EBLV-2 was 
estimated to have appeared during the last 2000 years. However, EBLV-2 and 
other phylogroup I viruses were estimated to have already diverged from other 
lyssaviruses at about 8000 years ago (Fig. 11). The divergence of Finnish EBLV-
2 strains and a strain from Switzerland from other EBLV-2 strains has occurred 
during the last 1000 years. The two Finnish strains have evolved from a common 
ancestor during the last 200 years.
The EBLV-2 isolate from Daubenton’s bat in 2016 (GenBank accession number 
MF326269) was 98% identical with the two other EBLV-2 isolates of 1985 and 
2009. This 2016 isolate and a new strain from a Daubenton’s bat from Norway 
are included in Figure 12.
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Figure 9. Phylogenetic tree of bat-related lyssaviruses based on whole genome sequences 
available.  
In order to include more EBLV-2 strains, we calculated phylogenetic trees (Fig. 10) 
based on partial N gene sequences. EBLV-2 strains were also monophyletic in this region. 
Some discrepancies were observed between the two trees, especially in the composition of 
the major clusters that were not reproduced in the phylogeny based on partial N-gene 
sequences. 
EF157977 EBLV-2 Homo sapiens GB 2002  
KF155004 EBLV-2 M. daubentonii GB 2004  
EU293114 EBLV-2 M. dasycneme NL 1986  
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 EF614261 KHUV M. Mystacinus TJ 2001
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 EF614258 WCBV Miniopterus Schreibersi RU 2002
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Figure 9. Phylogenetic tree of bat-related lyssaviruses based on whole genome sequences available. 
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 AY212117 M. daubentonii CH 1992
 AY863408 NA CH 1993
 KF831571 M. daubentonii CH 2002
 GU227648 M. daubentonii DE 2007
 JQ796805 M. daubentonii DE 2006
 KF826149 M. daubentonii DE 2013
 U89478 M. daubentonii GB 1996
 JQ796809 M. daubentonii GB 2006
 EF157977 Homo sapiens GB 2002
 JQ796811 M. daubentonii GB 2008
 KF155004 M. daubentonii GB 2004
 JQ796807 M. daubentonii GB 2004
 JQ796810 M. daubentonii GB 2007
 JQ796812 M. daubentonii GB 2008
 AY212120 M. daubentonii GB 2002
 JQ796808 M. daubentonii GB 2003
 JQ796806 M. daubentonii GB 2009
 AY062089 M. dasycneme NL 1989
 EU293114 M. dasycneme NL 1986
 U89480 M. dasycneme NL 1987
 AY863404 M. dasycneme NL 1993
 N9337 M. daubentonii CH 1993 
 AY212118 M. daubentonii CH 1993 
 GU992316 M. daubentonii CH 1993  
U89479 M. daubentonii CH 1993  
JX129232 M. daubentonii FI 2009  
JX129233 Homo sapiens FI 1985
 EF614261 KHUV M. Mystacinus TJ 2001
 KF24592 BBLV M. nattereri DE 2012
 JF311903 BBLV M. nattereri DE 2010
 EF614259 ARAV Myotis Blythi KG 1991
 NC003243 ABLV Pteropus sp AU 1996
 AF418014 ABLV Homo sapiens AU 1996
 KT868956 ABLV Pteropus scapulatus AU 2014
 KU244269 GBLV Pteropus giganteus LK 2015
 EU293113 RABV dog ex bat GF 1990
 AB519642 RABV D. rotundus BR 2000
 FJ905105 IRKV Murina leucogaster RU 2007
 JX442979 IRKV Murina leucogaster CH 2012
 EU293119 DUVV Homo sapiens ZA 1971
 EU293109 EBLV-1 Eptesicus serotinus FR 2003
 EF157976 EBLV-1 E. serotinus DE 1968
 EU293110 LBV Eidolon helvum NG 1956
 GU170201 SHIBV Hipposideros commersoni KE 2009
 NC006429 MOKV shrew NG 1968
 KF155007 MOKV feline ZW 1993
 EF614258 WCBV Miniopterus Schreibersi RU 2002
 JX402204 LLBV M. schreibersi ES 2012
 JX193798 IKOV Civettictis civetta TZ 2009
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EBLV-2 
Figure 10. Phylogenetic tree of bat-related lyssaviruses based on partial N-gene sequences.
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The substitution rate of European bat lyssavirus type 2 was estimated using the two 
Finnish strains isolated 24 years apart as a calibrator. The overall rate was 7.67 x 10-5 
substitutions per site per year. The current diversity of EBLV-2 was estimated to have 
appeared during the last 2000 years. However, EBLV-2 and other phylogroup I viruses were 
estimated to have already diverged from other lyssaviruses at about 8000 years ago (Fig. 
11). The divergence of Finnish EBLV-2 strains and a strain from Switzerland from other 
EBLV-2 strains has occurred during the last 1000 years. The two Finnish strains have 
evolved from a common ancestor during the last 200 years. 
 
 
Figure 11. Phylogenetic tree of EBLV-2 based on partial N-gene (400 nt) sequences with a 
molecular-clock estimate. The program BEAST was used to estimate the substitution rate of EBLV-
2 and time of divergence from the phylogenetically closest lyssavirus species. The HKY model of 
nucleotide substitution was used, and both strict and relaxed lognormal clock models. Convergence 
of parameters was assessed using TRACER, and each run was continued until the effective sampling 
size of all parameters was greater than 200. 
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Figure 11. Phylogenetic tree of EBLV-2 based on partial N-gene (400 nt) sequences with a molecular-
clock estimate. The program BEAST was used to estimate the substitution rate of EBLV-2 and time of 
divergence from the phylogenetically closest lyssavirus species. The HKY model of nucleotide substitution 
was used, and both strict and r laxed lo normal clock models. Convergence of parameters was assessed 
using TRACER, and each run was continued until the eective sampling size of all parameters was 
greater than 200.
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The EBLV-2 isolate from Daubenton’s bat in 2016 (GenBank accession number 
MF326269) was 98% identical with the two other EBLV-2 isolates of 1985 and 2009. This 
2016 isolate and a new strain from a Daubenton’s bat from Norway are included in Figure 
12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Phylogenetic tree of EBLV-2 lyssaviruses based on partial N-gene sequences. 
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Figure 12. Phylogenetic tree of EBLV-2 lyssaviruses based on partial N-gene sequences.
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5.4 Challenge of mice with RABV and EBLV-2 after   
 vaccination with a human vaccine and an animal   
 vaccine (III)
When challenged with RABV isolated from a Finnish raccoon dog in 1989, all 
of the vaccinated mice survived. When challenged with EBLV-2 isolated from a 
Daubenton’s bat in 2009, 75% to 80% of the vaccinated mice survived (Table 8). 
All vaccinated mice developed sufficient to high VNA titers against RABV ranging 
from 0.5 to 128 IU/ml. Mice that succumbed after challenge with EBLV-2 virus 
had a VNA titer of 2–64 IU/ml against RABV (individual results not shown).
From the group of 20 mice vaccinated with Rabisin, 11 died or were euthanized 
on the day of intra-cranial challenge with RABV and EBLV-2, while 12 and 8 
mice vaccinated with SAG2 oral live vaccine died or were euthanized at the intra-
cranial challenge with RABV and EBLV-2, respectively, and the experiment was 
discontinued. The experiment was repeated after modification with the vaccine 
Rabisin.
Table 8. Rabies vaccination protection following an intra-cranial challenge in mice
Survival after challenge with
Total 
number
of mice
RABV 1989 EBLV-2 2009
n (%) n (%)
Rabies Imovax, vaccinated twice 20 20 (100) 16 (80)
P-value1) 0.000 0.002
Rabies Imovax, vaccinated once 20 ND 15 (75)
P-value1) 0.005
Virus control 50 MLD50 5 0 (0) 0 (0)
Virus control 5 MLD50 5 2 (40) 2 (40)
Virus control 0.5 MLD50 5 4 (80) 4 (80)
Rabisin, vaccinated once 20 20 (100) 16 (80)
P-value1) 0.002
Virus control 50 MLD50 5 0 (0) 0 (0)
Virus control 5 MLD50 5 2 (40) 2 (40)
Virus control 0.5 MLD50 5 3 (60) 4 (80)
1)P-value derived using Fisher’s exact test for the number of vaccinated and challenged mice 
that survived relative to the total and compared with the 50 MLD50 virus control mice
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5.5 Results of the serological and statistical analysis of   
 vaccinated dogs and cats (III)
Of the 10 071 dog samples analyzed during 2009–2013, 1073 (10.7%; 95% 
confidence interval CI 10.1–11.3) had a rabies antibody titer of <0.5 IU/ml. Of 
the 722 cats analyzed, only 25 (3.5%; 95% CI 2.3–5.0) had a rabies antibody titer 
of <0.5 IU/ml.
Younger dogs were associated with lower antibody titers (p < 0.05). Since there 
was a significant interaction between the variables dog age and the vaccine used, 
two multivariable logistic regression models for dogs were constructed: one for dogs 
up to one year old and another for older dogs. For younger dogs, vaccine C (Flury 
LEP vaccine) was used significantly more often than for older dogs (p < 0.05). For 
both age groups, dogs vaccinated with vaccine C only and those vaccinated with 
vaccine B (Pasteur RIV vaccine) only had a significantly higher risk of failing to 
reach an antibody level of 0.5 IU/ml in comparison to dogs vaccinated with vaccine 
A (Wistar-G52 vaccine) only. Additionally, for both age groups, vaccination with 
vaccine C only had the highest risk of failing to reach an antibody level of 0.5 IU/
ml. In younger dogs, these risks were higher than in older dogs. In younger dogs, 
if the time between vaccination and sampling was over three months, the risk of 
failing to reach an antibody level of 0.5 IU/ml was significantly higher than if the 
time span was shorter. In older dogs, the risk was higher if the time was over six 
months. For older dogs (over one year) of a larger size (>30 cm), the risk of failing 
to reach an antibody level of 0.5 IU/ml was greater. In younger dogs, those over 
60 cm had a higher risk compared to smaller dogs. 
In cats, we observed no statistically significant differences between the vaccines 
used. However, there was a similar tendency towards a higher risk of failing to 
reach an antibody level of 0.5 IU/ml for vaccination with vaccine C only compared 
to vaccination with vaccine A only. Cats that were vaccinated at the age of up to 
one year old had a significantly higher risk of failing to reach an antibody level of 
0.5 IU/ml than cats vaccinated at an older age. Similarly to dogs, cats that were 
sampled for testing three to six months or over six months after vaccination had 
a significantly higher risk of failing to reach an antibody level of 0.5 IU/ml than 
cats that had been sampled less than three months after vaccination.
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6 DISCUSSION
6.1 Epidemiology of bat lyssavirus in Finland
EBLV-2 has been isolated from Finnish Daubenton’s bats twice, in 2009 and 
in 2016. Both bats showed neurological signs before death. The locations are 
only circa 100 kilometers apart. Furthermore, antibodies against lyssavirus have 
been detected in Daubenton’s bats from the same geographical area. These data 
provide a strong indication that EBLV-2 is endemic in the Finnish Daubenton’s 
bat population. Due to the small number of samples from passive and active 
surveillance from other areas in Finland, the presence of lyssaviruses in other 
parts of the country remains unclear. 
Passive surveillance of bat rabies might be a sufficient surveillance method for 
obtaining information on the incidence of bat lyssavirus, but it does not provide 
information on the prevalence of lyssavirus infection in a certain population. Active 
sampling of oral swabs has rarely resulted in positive findings, and our findings 
are consistent with this, since we did not find a viral genome from swab samples 
tested in active surveillance. Moreover, active sampling requires permission from 
the competent authority due to the protection and conservation of bats, and is 
relatively expensive and labour-intensive. More samples from sick or dead bats 
should be sent for laboratory analysis. Daubenton’s bat samples are particularly 
difficult to obtain, probably because they do not usually roost in buildings, reducing 
the likelihood of people finding grounded bats. This leads to lower passive sampling 
of this species in comparison to other bat species. There is a significant correlation 
between the number of bats examined and the number of positive bats. Harris et 
al. (2007) suggested that seven or more dead or symptomatic Daubenton’s bats 
should be examined yearly in order to find at least one EBLV-2-positive sample. 
In Finland, 2 out of 15 Daubenton’s bats sampled in passive surveillance during 
1985–2016 were positive for EBLV-2.
Serological testing can be used as an indicator of past exposure to lyssavirus 
in bats. Seropositive Daubenton’s bats have been recorded in Finland and also in 
the UK, Switzerland, Sweden and Latvia. Results from our surveillance indicate 
that the lyssavirus seroprevalence in the Finnish bat population is low, even 
though all seropositive sampling sites exhibited high Daubenton’s bat densities 
and consisted of individuals of the same large population (Laine et al. 2013). 
The seroprevalence of Daubenton’s bats has also been low in other countries. 
The results of serosurveillance are not fully comparable because of differences 
in the methods used, as well as in the threshold values. In addition, the different 
lyssavirus-induced antibodies cross-react to some extend in laboratory analysis. 
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In an experimental infection, Daubenton’s bats were infected with EBLV-2, but 
none of the bats seroconverted (Johnson et al. 2008). Seroconversion appears to 
depend not just on the lyssavirus species infecting the bat, but also on the viral dose, 
bat species infected and route of exposure (Franka et al. 2008). Seroprevalence 
probably underestimates the true prevalence of lyssavirus infections in the bat 
population.
Of the 13 bat species recorded in Finland, Daubenton’s bats, pond bats (Myotis 
dasycneme), serotine bats (E. serotinus), Natterer’s bats (M. nattereri), whiskered 
bats (M. mystacinus), common pipistrelle (P. pipistrellus), Nathusius’ pipistrelle 
(P. nathusii) and common long-eared bat (Plecotus auritus) have been shown to be 
infected with lyssaviruses. Myotis dasycneme, the bat species associated with EBLV-
2 infections in the Netherlands, and M. nattereri, the bat species associated with 
Bokeloh bat lyssavirus infections in Germany and France, are rare in Finland. Only 
a few observations of the species E. serotinus, the main reservoir host for EBLV-1 
infections, have so far been recorded in Finland. The first observation of E. serotinus 
was made in 2008. The most common bat species in Finland is the northern bat 
(Eptesicus nilssonii), which has not been associated with lyssavirus infections. 
The common bent-wing bat, or Schreibers’ bat (Miniopterus schreibersii), the 
greater tube-nosed bat (Murina leucogaster), the lesser mouse-eared bat (Myotis 
blythii), Commerson’s leaf-nosed bat (Hipposideros commersoni), and Pteropus 
spp., associated with several lyssavirus species infections, have never been recorded 
in Finland. Furthermore, the presence of different bat species in separate parts 
of the country is not fully known. It can be speculated that climate change might 
influence the geographical distribution of different bat species and therefore also 
the distribution of lyssaviruses (McIntyre et al. 2017).
Nevertheless, we consider the health risk to the general public as negligible 
when people have no contact with bats through work or hobbies. However, new 
lyssaviruses have recently been discovered, and it is possible that there may still 
be undetected bat lyssaviruses in many parts of the world. Resident bat species 
in Finland could also be infected with other lyssaviruses than EBLV-2. Proper 
handling of bats in order to avoid bites and subsequent exposure, and protecting 
houses from bats entering them are the most effective preventive measures against 
bat-induced lyssavirus infections. Education about bats and possible zoonotic 
diseases they might have, without inducing unnecessary fear, is very important 
to enable the peaceful co-existence of humans, domestic animals, and bats. In 
case exposure does occur, people should be aware of the need to seek medical 
advice for themselves and veterinary advice for their domestic animals. Health care 
workers and veterinarians also need to be informed about the necessary actions and 
legislation in place in order to implement proper measures after possible exposure 
to lyssaviruses. People who come into contact with bats due to their work or hobby, 
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should be vaccinated against rabies, even though current rabies vaccines induce 
only partial cross-protection against other lyssaviruses than RABV.
6.2 Phylogenetic analysis of Finnish EBLV-2 isolates 
EBLV-2 has been isolated in Finland from a diseased bat researcher in 1985 and 
from Daubenton’s bats in 2009 and 2016. All Finnish EBLV-2 isolates are very 
closely related and share high nucleotide identity. The overall organization and 
length of the regions of fully characterized EBLV-2 isolates of 1985 and 2009 were 
similar to the other three EBLV-2 isolates fully characterized. Comparison with 
other EBLV-2 sequences demonstrates a high degree of homology (Marston et al. 
2007, Delmas et al. 2007, Marston et al. 2013). 
EBLV-2 isolates cluster according to the host species, but also according to the 
geographical place of isolation. These are correlated, since EBLV-2 has been isolated 
from Daubenton’s bats in the UK, Germany, Switzerland, Finland, Denmark, and 
Norway and from the pond bat (M. dasycneme) in the Netherlands. The closest 
relatives to EBLV-2 are Bokeloh bat lyssavirus isolate from Myotis nattereri and 
Khujand virus isolate from Myotis mystacinus. Thus, the host species of these 
lyssavirus species are also related. EBLV-2 additionally shared ancestry with 
Aravan virus and with a lineage consisting of rabies virus RABV and Australian 
bat lyssavirus. Another major cluster of lyssaviruses consists of IRKV, DUVV, and 
EBLV-1, suggesting that EBLV-1 and EBLV-2 diverged a long time ago. The tree 
topology was somewhat different in the phylogeny based on either the complete 
coding sequences or the partial N sequences. 
In earlier studies, it has been suggested that the Finnish strain from 1985 and a 
strain from Switzerland 1993 form lineage EBLV-2b, whereas the rest of the EBLV-2 
isolates from the UK and the Netherlands form lineage EBLV-2a (Amengual et al. 
1997, McElhinney et al. 2013, Megali et al. 2010, Davis et al. 2005). In our study, 
there was a division into subgroups when full genomes were compared (Fig. 9). 
Unfortunately, the full genome of the Swiss strain was not available for analysis, 
and only strains from the UK and Germany were available. When more strains were 
compared using N-gene sequences, we could not confirm the suggested subgroup 
division (Figs 10 and 12). 
It has been shown that the genetic structure of Daubenton’s bats is relatively 
homogeneous in western parts of Europe. Daubenton’s bats migrate between the 
UK and the mainland of Europe. This supports the clustering of EBLV-2 according 
to the geographical place of isolation from the western parts of Europe (Smith et 
al. 2011). This could be the explanation for the proposed lineage 2a. As Finnish 
Daubenton’s bats do not migrate to Central Europe, the finding that the Finnish 
EBLV-2 is closely related to the EBLV-2 strain from Switzerland cannot be explained 
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by migration. Interpretation of the molecular epidemiology of these strains is 
further complicated by the history of the Swiss bat biologist who died of EBLV-
2 infection in Finland in 1985. He was bitten 51 days before the onset of clinical 
signs by a Daubenton’s bat, which showed signs of clinical rabies. Unfortunately, 
the bat was freed before the patient developed symptoms and it was not therefore 
available for laboratory tests (Roine et al. 1988). It can be speculated whether the 
freed bat was not originally from Finland (Lumio et al. 1986, Roine et al. 1988). 
The current linage of EBLV-2 arose circa 2000 years ago. The most recent 
common ancestor (TMRCA) occurred circa 8000 years ago. The Finnish EBLV-
2 strains and a Swiss strain have evolved from a common ancestor during the 
last 1000 years (Figure 12). Tao et al. (2013) estimated that the TMRCA of all 
lyssaviruses was approximately 5030 years. The West Caucasian bat virus divided 
first, and phylogroups I and II then divided about 4000 years ago. The overall rate 
of evolution appears somewhat slower for the bat-type lyssaviruses than for RABV. 
This is in line with bats being considered the true reservoir of lyssaviruses. The 
overall evolution rate for EBLV-2 in our study was 7.67 x 10-5 substitutions per site 
per year (95% HPD interval). For RABV, it has been suggested to be 1.56–1.78 x 10-4 
(Kuzmina et al. 2013) and 1 x 10-3 to 5.5 x 10-4 (Bourhy et al. 1992, Hughes 2008, 
Badrane and Tordo 2001, Hanada 2004). Timescale estimation performed on a 
limited set of recently sampled sequences cannot provide realistic inferences for 
viruses evolving under the constraints of purifying selection. Evolutionary rates are 
increased towards the present because of the transient mutations yet to be removed 
by purifying selection. Therefore, timescale estimations based on substitution rates 
are useful for the time frame encompassed by the sampling period. They cannot 
be easily extrapolated for longer periods of time (Rupprecht et al. 2017).
Streicker et al. (2012) demonstrated that the local host environment determines 
lyssavirus evolutionary rates. Hibernation, migration, and the coloniality of the 
bats might influence viral evolution (Streicker et al. 2012, Mollentze et al. 2014). 
Virus evolution in lineages in bat species from tropical or subtropical climates 
and in bats that remain active year-round was faster in comparison to bats in the 
temperate climate zone and to those bats that hibernate. This could be a major factor 
in a cold climate region. Lyssaviruses associated with closely related bat species 
or sub-species often had dissimilar evolutionary rates. Increased information on 
the complete genome sequences of lyssaviruses is fundamental to understanding 
their epidemiology and evolution. It is important to monitor and characterize 
lyssaviruses circulating in human and animal populations. For a detailed analysis of 
evolutionary history, complete genomes should be used. The limitation of our study 
was the number of whole genome sequences available for comparison. Streicker 
et al. (2016) demonstrated that with adequate data on both the virus and the host 
and with accurate models, it would be possible to predict the timing and location 
of the emergence of disease from animals to humans (Streicker et al. 2016).
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Some bat species have an extensive geographical distribution, while others 
appear to have a very restricted geographical distribution. Also, some lyssaviruses 
are able to infect a wide range of bat species, while others are only found in certain 
species. The underlying reasons for virus-host restrictions and the differences in 
habitation tendencies are still unknown. For many lyssavirus species, only a few 
isolates or just a single isolate are available, which makes it difficult to study host 
and viral properties.
6.3 Rabies vaccination and protection against EBLV-2 
VNAs are the main method of protection during rabies infection, and the role of 
cell-mediated and innate immunity is not as well understood, even though both 
play an important role. Measuring the VNA titer is the most common way to assess 
the success of rabies vaccination. Challenge by using vaccinated laboratory animals 
is another way of studying the potency of a rabies vaccine.
The immune response elicited by RABV-based rabies vaccines has been shown 
to be capable of cross-protection against other lyssaviruses in phylogroup I, but 
not for those that belong to phylogroup II or potential new phylogroups (Liu 2013, 
Hanlon 2005, Malerzyk 2009 and 2014, Fekadu 1988). Even though EBLV-2 and 
RABV both belong to phylogroup I, the protection induced by rabies vaccines has 
been limited in experimental virus challenge studies in mice, even with production 
of VNAs (Brookes et al. 2005, Fekadu 1988). Separate studies have drawn different 
conclusions on cross-protection, but information is still limited and factors such 
as the virus strain, type of cell culture used for vaccine production, and the use of 
adjuvants of the vaccine influence the vaccination response. 
Possible exposure to other lyssaviruses than RABV has raised concern over 
whether RABV-based vaccines offer sufficient protection. Studies have suggested 
that either higher serum VNA titers (Brookes et al. 2005) or a higher dose of rabies 
immunoglobulins is required to neutralize other lyssaviruses than RABV (Liu et al. 
2013). The development of novel vaccines that would stimulate a pan-lyssavirus 
neutralizing immune response is of importance to those at occupational risk of 
infection with lyssaviruses divergent from RABV (Evans et al. 2012). Considering 
that vaccine development is time consuming, laborious, and expensive, pan-
lyssavirus vaccines are not expected in the near future and protection against 
lyssaviruses other than phylogroup I relies on the prevention of exposure and 
thorough wound care.
There is marked individual variation in the comparative neutralization patterns 
of human sera against different lyssaviruses (Brookes et al. 2005, Horton et al. 
2010), and this is probably also true for animals. In our study, all mice developed 
a sufficient VNA titer against RABV after vaccination, but mice that had VNA 
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titers of 2–64 IU/ml, which is higher than the accepted threshold, succumbed 
after challenge with EBLV-2 virus. All vaccinated mice survived the challenge with 
RABV. This indicates that the RABV antibody level does not clearly correlate with 
protection against EBLV-2. Therefore, it is still unclear what RABV antibody level 
would be indicative of protection. 
When we first started our potency test, the mice vaccinated with animal vaccines 
suffered from an anaphylactic reaction with a fatal outcome during and immediately 
after challenge with the virus suspension. They started breathing heavily, stopped 
moving, their extremities turned blue, and despite our efforts to support their 
critical functions, died or were euthanized after a few minutes. This was not seen 
in mice vaccinated with human vaccine or when the virus suspension was prepared 
in physiological saline instead of MEM. Therefore, we started using physiological 
saline in the virus suspension and we did not encounter any further problems of 
this kind. This unforeseen reaction was probably due to the purification process 
during manufacture. In general, veterinary vaccines often are less purified than 
human vaccines. This is reflected in the prices of the vaccines; the human product 
has on average a ten-fold higher price than animal parental rabies vaccines.
6.4 Factors influencing the success of rabies vaccination  
 of the dog and cat population in Finland
The difference between the proportions of dogs (around 11%) and cats (around 
3%) failing to reach the level of 0.5 IU/ml is an interesting finding. This might be 
caused by differences in genetic variation within these two species. Most dogs in 
our study material were pedigree dogs, whereas the majority of cats were barn 
cats. Moreover, cats are more homogeneous in size and there is much greater 
variability in size between dogs of different breeds. The key genetic factor of immune 
responsiveness is situated within the major histocompatibility complex (MHC). It 
has been suspected that the cat has a more limited diversity in immune response 
genes than dogs, but recent research has revealed variation in the MHC in cats, 
as is found in dogs (Day 2007). In our study, the different commercial vaccines 
induced the antibody level of 0.5 IU/ml differently in dogs. This has also been 
shown in other earlier studies (Berntsson et al. 2011, Mansfield et al. 2004, Minke 
et al. 2008, Kennedy et al. 2007). This difference between the vaccines was not 
statistically significant in cats, perhaps due to the type two error of too small sample 
sizes, since there were so few (n = 25) failures to reach 0.5 IU/ml in cats. Clearly, 
veterinarians should be aware of the differences between vaccines in their ability 
to induce antibody production, especially when they are vaccinating dogs with a 
higher risk of failing to reach the required antibody level.
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Several factors influence the outcome of an animal’s antibody level after 
vaccination, namely the vaccine used, the vaccination procedure, and the animal 
receiving vaccination. Sihvonen et al. (1995) demonstrated that a single vaccination 
of dogs with rabies vaccine induced moderate but short-term seroconversion in 
96.9% of dogs, but in 17% of dogs the antibody titer did not last for a whole year. 
Based on our studies, it is advisable that dogs needing a sufficient antibody test 
result due to travel or those that will be going to rabies endemic areas should 
be vaccinated twice with rabies vaccine and then regularly boosted according to 
the manufacturer’s instructions, and the choice of vaccine needs to be taken into 
consideration. 
The time between vaccination and sampling was a significant risk factor for both 
dogs and cats failing to reach the antibody level of 0.5 IU/ml. The antibody level 
peaks at slightly different times after vaccination depending on the vaccine, and the 
level starts to decline afterwards (Mansfield et al 2004). Larger dogs had a greater 
risk of failing to reach the required antibody level. Increasing the dose would not 
probably be a solution, since it has been shown that if there is a sufficient antigen 
to create a response, larger doses will not increase antibody production. Kennedy 
et al. (2007) suggested that larger breeds might have deeper sub-cutaneous fat, 
which could reduce the level of the antibody response. The breed might also be 
a factor, not just the size of the dog, since even though most failures to reach the 
anticipated antibody level were in larger breeds, some smaller breeds had significant 
test failure rates (Kennedy et al. 2005). The higher risk of failing to reach 0.5 IU/
ml in dogs and cats aged under one year old could be due to the administration of 
vaccines before the animal has reached full immunocompetency or due to maternal 
antibodies (Mansfield et al. 2004, Berndtsson et al. 2011).
In rabies-free countries, the rabies vaccination coverage of cats and dogs is likely 
to be smaller than in rabies-endemic countries. Furthermore, the legislation does 
not usually include mandatory vaccinations in rabies-free countries. For example, 
in Finland, we estimated based on the number of vaccine doses (other vaccines 
than rabies vaccines) sold that about 10–20% of cat population of circa 700 000 
has been vaccinated. The vaccination coverage for rabies vaccines is probably even 
lower than this. The dog population in Finland has been estimated to be around 
650 000 (Finnish Kennel Club 2014). The rabies vaccination coverage is higher 
for dogs than cats, estimated at around 40–65% based on the number of rabies 
vaccines sold in Finland (personal communication Martina Reims). Cats, especially 
in the countryside, often freely go outside and are therefore able to encounter 
wildlife. They are consequently at greater risk of exposure to rabid animals and 
especially to bats than dogs. Natural spillover of EBLV-2 to other mammals than 
humans has not been demonstrated. Even though EBLV-2 infection of dogs and 
cats through bat contact is very unlikely to occur due to the low prevalence of 
lyssavirus in the bat population and the small likelihood of such an encounter, dogs 
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and cats are probably susceptible to EBLV-2 infection. Dogs and cats vaccinated 
against rabies are highly likely to be protected against EBLV-2 infection as well. 
However, it has to be remembered that protection against succumbing to rabies 
and measuring antibody titers in order to see that vaccination has succeeded are 
two different aspects.
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7 CONCLUSIONS
1. EBLV-2 circulates in bats in Finland, even though the seroprevalence is low. Our 
results indicate that passive surveillance of dead or sick bats is a relevant means 
to study the occurrence of lyssavirus infection, but the number of bats submitted 
for laboratory analysis should be higher and from a wider geographical area in 
order to obtain reliable information on the lyssavirus situation in the country.
2. In Finland, the health risk to people who have no contact with bats through 
work or hobbies is considered negligible.
3. The three EBLV-2 strains isolated in Finland are highly similar to each other 
but also with other EBLV-2 strains characterized.
4. The results from the mouse model indicate that dogs and cats vaccinated with 
RABV-based rabies vaccines are cross-protected against EBLV-2. 
5. The mouse model also indicated that people vaccinated with RABV-based 
vaccines with an antibody titer ≥0.5 IU/ml are most probably protected against 
EBLV-2. However, measurement of the RABV antibody titer only provides a 
partial indication of protection against EBLV-2.
6. Dogs, and especially cats, seldom fail to reach the antibody titer of 0.5 IU/
ml after rabies vaccination, but several risk factors for dogs and some for cats 
failing to reach this level were identified.
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